Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
A malignant epithelial tumor with a glandular organization.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A cell line derived from cultured tumor cells.
INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Surgical removal of the pancreas. (Dorland, 28th ed)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Tumors or cancer of the human BREAST.
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
Tumors or cancer of the LIVER.
The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The fluid containing digestive enzymes secreted by the pancreas in response to food in the duodenum.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Cells lining the saclike dilatations known as acini of various glands or the lungs.
Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A signal transducing adaptor protein and tumor suppressor protein. It forms a complex with activated RECEPTOR-REGULATED SMAD PROTEINS. The complex then translocates to the CELL NUCLEUS and regulates GENETIC TRANSCRIPTION of target GENES.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A condition in which there is a change of one adult cell type to another similar adult cell type.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Tumors or cancer of the NASOPHARYNX.
DNA present in neoplastic tissue.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the THYROID GLAND.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Small, monomeric GTP-binding proteins encoded by ras genes (GENES, RAS). The protooncogene-derived protein, PROTO-ONCOGENE PROTEIN P21(RAS), plays a role in normal cellular growth, differentiation and development. The oncogene-derived protein (ONCOGENE PROTEIN P21(RAS)) can play a role in aberrant cellular regulation during neoplastic cell transformation (CELL TRANSFORMATION, NEOPLASTIC). This enzyme was formerly listed as EC
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Tumors or cancer of the LUNG.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
RNA present in neoplastic tissue.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Star-shaped, myofibroblast-like cells located in the periacinar, perivascular, and periductal regions of the EXOCRINE PANCREAS. They play a key role in the pathobiology of FIBROSIS; PANCREATITIS; and PANCREATIC CANCER.
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
A class of compounds that contain a -NH2 and a -NO radical. Many members of this group have carcinogenic and mutagenic properties.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
A benign neoplasm of the ovary.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Basic glycoprotein members of the SERPIN SUPERFAMILY that function as COLLAGEN-specific MOLECULAR CHAPERONES in the ENDOPLASMIC RETICULUM.
One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
The conic organs which usually give outlet to milk from the mammary glands.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.
Pathological processes of the PANCREAS.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Tumors or cancer of the ESOPHAGUS.
Elements of limited time intervals, contributing to particular results or situations.
Tumors or cancer of the MOUTH.
A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.
Transplantation between animals of different species.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface.
A gel-forming mucin found predominantly in SMALL INTESTINE and variety of mucous membrane-containing organs. It provides a protective, lubricating barrier against particles and infectious agents.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
A homolog of ALPHA-SYNUCLEIN that plays a role in neurofilament network integrity. It is overexpressed in a variety of human NEOPLASMS and may be involved in modulating AXON architecture during EMBRYONIC DEVELOPMENT and in the adult. Gamma-Synuclein may also activate SIGNAL TRANSDUCTION PATHWAYS associated with ETS-DOMAIN PROTEIN ELK-1.
Tumors or cancer of the COLON.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins.
Tumors or cancer of the URINARY BLADDER.
Tumors or cancer of the STOMACH.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.
Tumors or cancer of the SKIN.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
An abnormal concretion occurring mostly in the urinary and biliary tracts, usually composed of mineral salts. Also called stones.
Cyst-like space not lined by EPITHELIUM and contained within the PANCREAS. Pancreatic pseudocysts account for most of the cystic collections in the pancreas and are often associated with chronic PANCREATITIS.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
MAMMARY GLANDS in the non-human MAMMALS.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Interruption or suppression of the expression of a gene at transcriptional or translational levels.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
Antibodies produced by a single clone of cells.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Any of the ducts which transport saliva. Salivary ducts include the parotid duct, the major and minor sublingual ducts, and the submandibular duct.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
The period before a surgical operation.
Procedures of applying ENDOSCOPES for disease diagnosis and treatment. Endoscopy involves passing an optical instrument through a small incision in the skin i.e., percutaneous; or through a natural orifice and along natural body pathways such as the digestive tract; and/or through an incision in the wall of a tubular structure or organ, i.e. transluminal, to examine or perform surgery on the interior parts of the body.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Tumors or cancer of the UTERINE CERVIX.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Methods used for detecting the amplified DNA products from the polymerase chain reaction as they accumulate instead of at the end of the reaction.
A fetal blood vessel connecting the pulmonary artery with the descending aorta.
A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level. (USAN and the USP Dictionary of Drug Names, 1994, p597)
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.
A genus of the family Muridae having three species. The present domesticated strains were developed from individuals brought from Syria. They are widely used in biomedical research.
The smallest member of the MATRIX METALLOPROTEINASES. It plays a role in tumor progression.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Phenotypic changes of EPITHELIAL CELLS to MESENCHYME type, which increase cell mobility critical in many developmental processes such as NEURAL TUBE development. NEOPLASM METASTASIS and DISEASE PROGRESSION may also induce this transition.
Antimetabolites that are useful in cancer chemotherapy.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Established cell cultures that have the potential to propagate indefinitely.
Proteins encoded by homeobox genes (GENES, HOMEOBOX) that exhibit structural similarity to certain prokaryotic and eukaryotic DNA-binding proteins. Homeodomain proteins are involved in the control of gene expression during morphogenesis and development (GENE EXPRESSION REGULATION, DEVELOPMENTAL).
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Biochemical identification of mutational changes in a nucleotide sequence.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Tumors or cancer of the gallbladder.
The artificial induction of GENE SILENCING by the use of RNA INTERFERENCE to reduce the expression of a specific gene. It includes the use of DOUBLE-STRANDED RNA, such as SMALL INTERFERING RNA and RNA containing HAIRPIN LOOP SEQUENCE, and ANTI-SENSE OLIGONUCLEOTIDES.
Pathological processes of the BREAST.
A family of intercellular signaling proteins that play and important role in regulating the development of many TISSUES and organs. Their name derives from the observation of a hedgehog-like appearance in DROSOPHILA embryos with genetic mutations that block their action.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.

Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. (1/1051)

DPC4 (MADH4, SMAD4) encodes a nuclear transcription factor shown to be genetically inactivated in over one-half of conventional infiltrating ductal adenocarcinomas of the pancreas. Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas have been suggested to be distinct neoplasms with a significantly less aggressive course than conventional ductal adenocarcinomas of the pancreas, but molecular comparisons of these tumor types have previously been impaired by technical difficulties. Recently, immunohistochemical labeling for the DPC4 gene product has been shown to be an extremely sensitive and specific marker for DPC4 gene alterations in pancreatic adenocarcinomas. Therefore, we analyzed the immunohistochemical expression of Dpc4 protein in 79 IPMNs using a previously characterized monoclonal antibody. Twenty-nine of the IPMNs also had an associated infiltrating adenocarcinoma available for analysis. The labeling patterns observed were compared to those we have previously reported for conventional ductal carcinomas. All 79 of the intraductal components of the IPMNs strongly expressed Dpc4 protein. In 77 of the 79 cases (97%), the labeling was diffusely positive, and in 2 of the 79 (3%) the labeling was focally positive. Dpc4 expression was seen in 28 (97%) of the associated 29 invasive cancers. The one infiltrating carcinoma that showed loss of Dpc4 expression was associated with an intraductal component which showed focal loss of Dpc4 expression. The strong and almost universal expression of Dpc4 in IPMNs contrasts sharply with the loss of Dpc4 expression seen in approximately 30% of in situ adenocarcinomas of the pancreas (so-called pancreatic intraepithelial neoplasms, grade 3; P: < 0.001) and in 55% of pancreatic duct carcinomas (P: < 0.0001). Differences in Dpc4 expression between IPMNs and ductal carcinomas suggest a fundamental genetic difference in tumorigenesis, which may relate to the significantly better clinical outcomes observed for IPMNs.  (+info)

Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. (2/1051)

There continues to be a need for new systemic approaches for the treatment of advanced pancreatic cancer. The purpose of this study was to compare the antitumor activity of the somatostatin analogue octreotide to 5-fluorouracil chemotherapy in a Phase III setting. Eighty-four patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and limited tumor volume were randomized to receive octreotide 200 microg three times daily or 5-fluorouracil with or without leucovorin. After the first 12 patients had been randomized to octreotide, we increased the dose in the remaining patients to 500 microg three times daily. This change was based on early reports in other studies, suggesting that our original dose may not have been effective and that higher doses of octreotide were well tolerated. A planned interim analysis performed after 84 patients were enrolled demonstrated inferior time to progression and survival for the patients randomized to octreotide. Further accrual to the octreotide arm of this protocol was therefore terminated. Octreotide in doses of 200-500 microg three times daily does not delay progression or extend survival in patients with advanced pancreatic cancer compared with treatment with 5-fluorouracil with or without leucovorin.  (+info)

Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. (3/1051)

To examine the expression of the stromal cell-derived factor 1 (SDF-1)/CXCR4 receptor ligand system in pancreatic cancer cells and endothelial cells, we performed immunohistochemical analysis for 52 pancreatic cancer tissue samples with anti-CXCR4 antibody and reverse transcription-PCR analysis for CXCR4 and SDF-1 in five pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC, and PANC-1), an endothelial cell line (HUVEC), and eight pancreatic cancer tissues. We then performed cell migration assay on AsPC-1 cells, HUVECs, and CFPAC-1 cells in the presence of SDF-1 or MRC-9 fibroblast cells. Immunoreactive CXCR4 was found mainly in pancreatic cancer cells and endothelial cells of relatively large vessels around a tumorous lesion. The immunopositive ratio in the pancreatic cancer was 71.2%. There was no statistically significant correlation with clinicopathological features. SDF-1 mRNA expressions were detected in all pancreatic cancer tissues but not in pancreatic cancer cell lines and HUVECs; meanwhile, CXCR4 mRNA was detected in all pancreatic cancer tissues, cancer cell lines, and HUVECs. The results indicate that the paracrine mechanism is involved in the SDF-1/CXCR4 receptor ligand system in pancreatic cancer. In vitro studies demonstrated that SDF-1 significantly increased the migration ability of AsPC-1 and HUVECs, and these effects were inhibited by CXCR4 antagonist T22, and that the coculture system with MRC-9 also increased the migration ability of CFPAC-1 cells, and this effect was significantly inhibited by T22. Our results suggested that the SDF-1/CXCR4 receptor ligand system may have a possible role in the pancreatic cancer progression through tumor cell migration and angiogenesis.  (+info)

Multiple primaries in pancreatic cancer patients: indicator of a genetic predisposition? (4/1051)

BACKGROUND: The genetic basis of several familial cancers including breast and colon cancers has been identified recently. The occurrence of multiple cancers in one individual is also suggestive of a genetic predisposition. To evaluate inherited predisposition in pancreatic cancer we compared the clinical data of pancreatic cancer patients with and without multiple primaries as well as the frequency of malignancies among their relatives. METHODS: Detailed data on 69 pancreatic cancer patients included survival time and TNM-classification. Index case data were separated into two groups. The first group (group 1) developed only pancreatic cancer during their lifetime, whereas the second group (group 2) developed additional primary tumours. A systematic family history was taken from 59 of these pancreatic cancer patients using a standardized questionnaire. The pancreatic cancers and the multiple primaries of the 59 patients were histologically proven. RESULTS: Of the 69 pancreatic cancer patients, 13 (18.8%) had multiple primaries. Neither the clinical data nor the survival data of the index cases revealed differences between the two groups (all nominal P-values >0.05). In the family history study blood relatives developed a malignancy in 51% (24 of 47) of the families in group 1 compared to 75% (9 of 12) in group 2. The risk of relatives in group 2 of developing a malignant tumour was significantly higher (P = 0.034) than in group 1 after adjustments for family size and age of disease onset of the index case. The cancer spectrum of the 59 families mainly included tumours of the digestive tract and the reproductive organs. CONCLUSIONS: A multiple primary cancer history is a common condition among pancreatic cancer patients. Relatives of these patients seem to have an increased risk for the development of distinct malignant solid tumours, which might be caused by an inherited predisposition. Clinical and genetic investigation of pancreatic cancer patients with multiple primaries and their families might lead to the identification of predisposing gene defects providing a new goal for the understanding of a shared genetic basis of different solid tumours.  (+info)

PGP9.5 as a prognostic factor in pancreatic cancer. (5/1051)

The expression of PGP9.5 was evaluated using immunohistochemistry in 69 resected ductal carcinomas of the pancreas and in normal pancreatic tissue. Overexpression did not seem to differ with histological type or pathological stage. A significant negative correlation was found between overexpression of PGP9.5 and postoperative survival. Multivariate analysis also suggested PGP9.5 along with tumor stage and extrapancreatic plexus invasion as strong predictors of the outcome. This study suggests that PGP9.5 expression may be used as a marker for predicting the outcome of resection-treated pancreatic cancer patients.  (+info)

Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. (6/1051)

Alterations of K- ras, p53, p16 and DPC4/Smad4 characterize pancreatic ductal cancer (PDC). Reports of inactivation of these latter two genes in pancreatic endocrine tumours (PET) suggest that common molecular pathways are involved in the tumorigenesis of pancreatic exocrine and endocrine epithelia. We characterized 112 primary pancreatic tumours for alterations in p16 and DPC4 and immunohistochemical expression of DPC4. The cases included 34 PDC, 10 intraductal papillary-mucinous tumours (IPMT), 6 acinar carcinomas (PAC), 5 solid-pseudopapillary tumours (SPT), 16 ampulla of Vater cancers (AVC) and 41 PET. All tumours were also presently or previously analysed for K- ras and p53 mutations and allelic loss at 9p, 17p and 18q. Alterations in K- ras, p53, p16 and DPC4 were found in 82%, 53%, 38% and 9% of PDC, respectively and in 47%, 60%, 25% and 6% of AVC. Alterations in these genes were virtually absent in PET, PAC or SPT, while in IPMT only K- ras mutations were present (30%). Positive immunostaining confirmed the absence of DPC4 alterations in all IPMT, SPT, PAC and PET, while 47% of PDC and 38% of AVC were immunonegative. These data suggest that pancreatic exocrine and endocrine tumourigenesis involves different genetic targets and that among exocrine pancreatic neoplasms, only ductal and ampullary cancers share common molecular events.  (+info)

Expression of p8 in human pancreatic cancer. (7/1051)

The p8 gene is a recently identified gene with mitogenic activity. p8 expression is induced in acute pancreatitis, pancreatic development, and regeneration. However, the expression of p8 in pancreatic cancer is not reported. We investigated p8 expression in 72 human pancreatic tissues, including 38 pancreatic cancers (PCs), by immunohistochemistry. p8 was overexpressed (positive cells >25% in 1,000 cells) in 71% (27 of 38) of PCs, but in only 17% (3 of 18) of chronic pancreatitis cases. There was no overexpression in mucinous cystadenoma or in normal pancreas. The p8 overexpression rate in PC was significantly higher than that in other conditions (P < 0.05). Reverse transcription-PCR analysis confirmed p8 mRNA overexpression (tumor/nontumor ratio >2) in 75% (3 of 4) of PCs. p8 was overexpressed also in human pancreatic cancer cell lines (MIA PaCa-2 and PANC-1). These results suggest that p8 is involved in the development of pancreatic cancer, reflecting its mitogenic activity.  (+info)

Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. (8/1051)

The incidences of microsatellite instability (MSI) and underlying DNA mismatch repair (MMR) defects in pancreatic carcinogenesis have not been well established. We analyzed 100 sporadic and 3 hereditary pancreatic ductal adenocarcinomas for MSI, and high-frequency MSI (MSI-H) and low-frequency MSI (MSI-L) tumors were further analyzed for frameshift mutations of possible target genes and for promoter methylation and mutation of DNA MMR genes, including hMLH1, hMSH2, hMSH3, and hMSH6 genes. Among the 100 sporadic tumors, 13 (13%) were MSI-H, 13 (13%) were MSI-L, and 74 (74%) were microsatellite stable (MSS) tumors. All of the three hereditary tumors from hereditary nonpolyposis colorectal cancer (HNPCC) patients were MSI-H. MSI-H tumors were significantly associated with poor differentiation and the presence of wild-type K-RAS and p53 genes. Patients with MSI-H tumors had a significantly longer overall survival time than did those with MSI-L or MSS tumors (P = 0.0057). Frameshift mutations of hMSH3, hMLH3, BRCA-2, TGF-beta type II receptor, and BAX genes were detected in MSI-H tumors. Hypermethylation of the hMLH1 promoter was observed in 6 (46%) of the 13 sporadic MSI-H tumors but not in any of the 3 hereditary MSI-H tumors or 13 MSI-L tumors. All of the 3 HNPCC cases had germ-line hMLH1 mutation accompanied by loss of heterogeneity or other mutation in the tumor. Our results suggest that pancreatic carcinomas with MSI-H represent a distinctive oncogenic pathway because they exhibit peculiar clinical, pathological, and molecular characteristics. Our results also suggest the principal involvement of epigenetic or genetic inactivation of the hMLH1 gene in the pathogenesis of pancreatic carcinoma with MSI-H.  (+info)

Pancreatic ductal adenocarcinoma has a poor prognosis due to late diagnosis and a lack of effective therapeutic options. Thus, it is important to better understand its molecular mechanisms and to develop more effective treatments for the disease. The ternary complex factor Net, which exerts its strong inhibitory function on transcription of proto-oncogene gene c-fos by forming ternary complexes with a second transcription factor, has been suspected of being involved in pancreatic cancer and other tumors biology. In this study, we found that the majority of pancreatic ductal adenocarcinoma tissues and cell lines had weak or no expression of Net, whereas significantly high level of Net expression occurred in paired adjacent normal tissues we studied. Furthermore, using in vitro and in vivo model systems, we found that overexpression of Net inhibited cell growth and survival and induced cell apoptosis in human pancreatic ductal adenocarcinoma cell PL45; the mechanisms by which Net inhibited the cell cycle
TY - JOUR. T1 - Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. AU - Misra, Sougat. AU - Moro, Carlos F.. AU - Del Chiaro, Marco. AU - Pouso, Soledad. AU - Sebestyén, A.. AU - Löhr, Matthias. AU - Björnstedt, Mikael. AU - Verbeke, Caroline S.. PY - 2019/12/1. Y1 - 2019/12/1. N2 - Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, which is mainly due to late diagnosis and profound resistance to treatment. The latter is to a large extent attributed to the tumor stroma that is exceedingly prominent in PDAC and engages in complex interactions with the cancer cells. Hence, relevant preclinical models of PDAC should also include the tumor stroma. We herein describe the establishment and functional validation of an ex vivo organotypic culture of human PDAC that is based on precision-cut tissue slices from surgical specimens and reproducibly recapitulates the complex cellular and acellular composition of PDAC, including its ...
In the present study, we found that the centrosomes in nearly all pancreatic ductal carcinomas displayed structural abnormalities, such as an increase in their number and size, and an irregular distribution. Quantitative analysis demonstrated a significant difference in centrosome number between normal and cancer cells. In addition, double-labeled immunofluorescence analysis of MIA PaCa-2 pancreatic cancer cells suggest that these aberrant centrosomes contribute to the assembly of multipolar spindles, which may result in the improper segregation of chromosomes during mitosis. These results are consistent with previous studies describing centrosome abnormalities in human malignant tumors of the breast, prostate, brain, lung, and colon (10 , 11) . To our knowledge, however, this is the first report to demonstrate centrosome abnormalities in pancreatic carcinoma.. The centrosome plays a key role in the organization of cytoplasmic microtubules, in the determination of cell polarity, and in the ...
TY - JOUR. T1 - Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. AU - Qian, Zhi Rong. AU - Rubinson, Douglas A.. AU - Nowak, Jonathan A.. AU - Morales-Oyarvide, Vicente. AU - Dunne, Richard F.. AU - Kozak, Margaret M.. AU - Welch, Marisa W.. AU - Brais, Lauren K.. AU - Da Silva, Annacarolina. AU - Li, Tingting. AU - Li, Wanwan. AU - Masuda, Atsuhiro. AU - Yang, Juhong. AU - Shi, Yan. AU - Gu, Mancang. AU - Masugi, Yohei. AU - Bui, Justin. AU - Zellers, Caitlin L.. AU - Yuan, Chen. AU - Babic, Ana. AU - Khalaf, Natalia. AU - Aguirre, Andrew. AU - Ng, Kimmie. AU - Miksad, Rebecca A.. AU - Bullock, Andrea J.. AU - Chang, Daniel T.. AU - Tseng, Jennifer F.. AU - Clancy, Thomas E.. AU - Linehan, David C.. AU - Findeis-Hosey, Jennifer J.. AU - Doyle, Leona A.. AU - Thorner, Aaron R.. AU - Ducar, Matthew. AU - Wollison, Bruce. AU - Laing, Angelica. AU - Hahn, William C.. AU - Meyerson, Matthew. AU - Fuchs, Charles S.. AU - Ogino, ...
TY - JOUR. T1 - Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. AU - Einama, Takahiro. AU - Kamachi, Hirofumi. AU - Nishihara, Hiroshi. AU - Homma, Shigenori. AU - Kanno, Hiromi. AU - Takahashi, Kenta. AU - Sasaki, Ayami. AU - Tahara, Munenori. AU - Okada, Kuniaki. AU - Muraoka, Shunji. AU - Kamiyama, Toshiya. AU - Matsuno, Yoshihiro. AU - Ozaki, Michitaka. AU - Todo, Satoru. PY - 2011/11. Y1 - 2011/11. N2 - Objectives: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma. Methods: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level ...
Osteopontin (OPN) is a secreted phospho-protein that confers on cancer cells a migratory phenotype. We have recently shown that nicotine, a risk factor in pancreatic ductal adenocarcinoma (PDA), induces an alpha7-nicotine acetylcholine receptor (α7-nAChR)-mediated increase of OPN in PDA cells. In this study, we tested nicotines effect on the expression of OPN splice variants (OPNa, b, c) in PDA cells. We also analyzed the correlation between patients smoking history with OPN and α7-nAChR levels. RT-PCR and UV-light-illumination of ethidium-bromide staining were used to examine the mRNA expression in tissue and PDA cells treated with or without nicotine (3-300 nM). Localization of total OPN, OPNc and α7-nAChR was analyzed by immunohistochemistry, and their mRNA tissue expression levels were correlated with the patients smoking history. PDA cells expressed varying levels of OPNa, OPNb, and α7-nAChR. Nicotine treatment selectively induced denovo expression of OPNc and increased α7-nAChR expression
Avarol is a sesquiterpenoid hydroquinone with potent cytotoxicity. Although resolving endoplasmic reticulum (ER) stress is essential for intracellular homeostasis, erratic or excessive ER stress can lead to apoptosis. Here, we reported that avarol selectively induces cell death in pancreatic ductal adenocarcinomas (PDAC), which are difficult to treat owing to the availability of few chemotherapeutic agents. Analyses of the molecular mechanisms of avarol-induced apoptosis indicated upregulation of ER stress marker BiP and ER stress-dependent apoptosis inducer CHOP in PDAC cells but not in normal cells, suggesting that avarol selectively induces ER stress responses. We also showed that avarol activated the PERK-eIF2α pathway but did not affect the IRE1 and ATF6 pathways. Moreover, CHOP downregulation was significantly suppressed by avarol-induced apoptosis. Thus, the PERK-eIF2α-CHOP signaling pathway may be a novel molecular mechanism of avarol-induced apoptosis. The present data indicate that avarol
Glycolytic cancer cells produce large quantities of lactate that must be removed to sustain metabolism in the absence of oxidative phosphorylation. The only venting mechanism described to do this at an adequate rate is H+-coupled lactate efflux on monocarboxylate transporters (MCTs). Outward MCT activity is, however, thermodynamically inhibited by extracellular acidity, a hallmark of solid tumours. This inhibition would feedback unfavourably on metabolism and growth, raising the possibility that other venting mechanisms become important in under-perfused tumours. We investigated connexin-assembled gap junctions as an alternative route for discharging lactate from pancreatic ductal adenocarcinoma (PDAC) cells. Diffusive coupling (calcein transmission) in vitro was strong between Colo357 cells, weaker yet hypoxia-inducible between BxPC3 cells, and very low between MiaPaCa2 cells. Coupling correlated with levels of connexin-43 (Cx43), a protein previously linked to late-stage disease. Evoked lactate
In February of this year the U.S. National Cancer Institute published an important overview of the state of the science and medicine of pancreatic cancer. We will comment on aspects of it from time to time in the future, but as it so comprehensive and precise, in a departure from our usual practice, we will show a copy it here (sans bibliography and figures) in our pancreatic cancer blog. The term Pancreatic Ductal Carcinoma is accurate and abbreviated PDAC in the original paper; here in the interests of a potential lay reader we will add in parentheses the term: pancreatic cancer.. Scientific Framework for Pancreatic Ductal Carcinoma Executive Summary Significant scientific progress has been made in the last decade in understanding the biology and natural history of pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer); major clinical advances, however, have not occurred. Although PDAC (pancreatic cancer) shares some of the characteristics of other solid malignancies, such as mutations ...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and, very often, ineffective medical and surgical therapeutic options. The treatment of patients with advanced unresectable PDAC is restricted to systemic chemotherapy, a therapeutic intervention to which most eventually develop resistance. Recently, nab-paclitaxel (n-PTX) has been added to the arsenal of first-line therapies, and the combination of gemcitabine and n-PTX has modestly prolonged median overall survival. However, patients almost invariably succumb to the disease, and little is known about the mechanisms underlying n-PTX resistance. Using the conditionally reprogrammed (CR) cell approach, we established and verified continuously growing cell cultures from treatment-naïve patients with PDAC. To study the mechanisms of primary drug resistance, nab-paclitaxel-resistant (n-PTX-R) cells were generated from primary cultures and drug resistance was verified in vivo, both in zebrafish and in athymic nude ...
Telomerase activity was measured in surgically resected tissues of 20 human pancreatic ductal carcinomas, 12 adenomas, 5 pancreatitis tissues, 14 normal pancreatic ducts, and 13 normal pancreatic tissues (primarily made up of acinar cells) using a PCR-based telomerase assay. Relative telomerase activity was expressed as the equivalent telomerase intensity of the number of cells of a human pancreatic cancer cell line, MIA PaCa-2, per microgram of protein in the tissue samples. The median value (25th percentile, 75th percentile) of relative telomerase activity in pancreatic carcinomas was 13.2 (3.58, 244), which was significantly higher relative to normal tissues, normal ducts, pancreatitis tissues, and adenomas (P , 0.0001). When the cutoff value of relative telomerase activity was set at 1.00 and 3.00, the positivity rates of telomerase activity in pancreatic ductal carcinomas were 100 and 80%, respectively. Some of the adenoma samples displayed a weak telomerase ladder. However, when ...
TY - JOUR. T1 - Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. AU - Palam, L. R.. AU - Gore, J.. AU - Craven, K. E.. AU - Wilson, J. L.. AU - Korc, M.. PY - 2015/10/1. Y1 - 2015/10/1. N2 - Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with marked chemoresistance and a 5-year survival rate of 7%. The integrated stress response (ISR) is a cytoprotective pathway initiated in response to exposure to various environmental stimuli. We used pancreatic cancer cells (PCCs) that are highly resistant to gemcitabine (Gem) and an orthotopic mouse model to investigate the role of the ISR in Gem chemoresistance. Gem induced eIF2 phosphorylation and downstream transcription factors ATF4 and CHOP in PCCs, and these effects occurred in an eIF2a-S51 phosphorylation-dependent manner as determined using PANC-1 cells, and wild type and S51 mutant mouse embryo fibroblasts. Blocking the ISR pathway in PCCs with the ISR inhibitor ISRIB or ...
Growing tumors are hypoxic and respond to microenvironmental stress through increased expression of the hypoxia inducible factor-1α (HIF-1α) transcription factor, resulting in an adaptive switch to glycolytic metabolism, angiogenic signaling, survival, and metastasis. HIF-1α expression is associated with tumor resistance to cytotoxic therapy and inferior patient outcomes. Pancreatic cancer is the most hypoxic of all solid tumors and remains refractory to current chemoradiotherapy. We have seen nuclear HIF-1α in 88% of human pancreatic ductal carcinoma but in only 16% of normal pancreas. Stroma adjacent to the pancreatic ductal carcinoma also showed HIF-1α in 43% of cases. We investigated the novel selective HIF-1α inhibitor PX-478 on in vitro and in vivo radiation response of human pancreatic cancer models. Inhibition of HIF-1α by PX-478 increased cell killing by radiation. In mice with Panc-1, CF-PAC-1, or SU.86.86 pancreatic xenografts, concurrent administration of PX-478 potentiated ...
Pancreatic ductal adenocarcinoma (PDAC) is usually incurable. Contrary to genetic mechanisms involved in PDAC pathogenesis, epigenetic alterations are ill defined. Here, we determine the contribution of epigenetically silenced genes to the development of PDAC. We analyzed enriched, highly methylated DNAs from PDACs, chronic pancreatitis (CP) and normal tissues using CpG island microarrays and identified WNK2 as a prominent candidate tumor suppressor gene being downregulated early in PDAC development. WNK2 was further investigated in tissue microarrays, methylation analysis of early pancreatic intraepithelial neoplasia (PanIN), mouse models for PDAC and pancreatitis, re-expression studies after demethylation, and cell growth assays using WNK2 overexpression. Demethylation assays confirmed the link between methylation and expression. WNK2 hypermethylation was higher in tumor than in surrounding inflamed tissues and was observed in PanIN lesions as well as in a PDAC mouse model. WNK2 mRNA and protein
TY - JOUR. T1 - Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics. AU - Murthy, Divya. AU - Attri, Kuldeep S.. AU - Singh, Pankaj K.. N1 - Funding Information: This work was supported in part by funding from the National Institutes of Health grant (R01 CA163649, R01 CA210439, and R01 CA216853, NCI) to PS and the Specialized Programs for Research Excellence (SPORE, 2P50 CA127297, NCI) to PS. We would also like to acknowledge the Fred & Pamela Buffett Cancer Center Support Grant (P30CA036727, NCI) for supporting shared resources. Publisher Copyright: © 2018 Murthy, Attri and Singh.. PY - 2018/4/4. Y1 - 2018/4/4. N2 - Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by its sudden manifestation, rapid progression, poor prognosis, and limited therapeutic options. Genetic alterations in key signaling pathways found in early pancreatic lesions are pivotal for the development and progression ...
The Wnt/β-catenin pathway has a key role in regulating cellular processes and its aberrant signaling can lead to cancer development. The role of β-catenin expression in pancreatic ductal adenocarcinoma is somewhat controversial. Transcription factor PROX1 is a target of Wnt/β-catenin signaling and it is involved in carcinogenesis through alterations in its expression. The actions can be either oncogenic or tumor suppressive depending on the tissue. The aim of this study was to investigate PROX1 and β-catenin expression in pancreatic ductal adenocarcinoma (PDAC). Expression of PROX1 and β-catenin were evaluated in 156 patients by immunohistochemistry of tissue microarrays. Associations between tumor marker expression and clinicopathological parameters were assessed by the Fischers exact-test or the linear-by-linear association test. The Kaplan-Meier method and log-rank test were used for survival analysis. Uni- and multivariate survival analyses were carried out by the Cox regression proportional
TY - JOUR. T1 - Pancreatic ductal adenocarcinoma radiology reporting template. T2 - Consensus statement of the society of abdominal radiology and the american pancreatic association. AU - Al-Hawary, Mahmoud M.. AU - Francis, Isaac R.. AU - Chari, Suresh T. AU - Fishman, Elliot K.. AU - Hough, David M.. AU - Lu, David S.. AU - Macari, Michael. AU - Megibow, Alec J.. AU - Miller, Frank H.. AU - Mortele, Koenraad J.. AU - Merchant, Nipun B.. AU - Minter, Rebecca M.. AU - Tamm, Eric P.. AU - Sahani, Dushyant V.. AU - Simeone, Diane M.. PY - 2014/1. Y1 - 2014/1. N2 - Pancreatic ductal adenocarcinoma is an aggressive malignancy with a high mortality rate. Proper determination of the extent of disease on imaging studies at the time of staging is one of the most important steps in optimal patient management. Given the variability in expertise and definition of disease extent among different practitioners as well as frequent lack of complete reporting of pertinent imaging findings at radiologic ...
Pancreatic cancer is among the most lethal malignancies worldwide. This study aimed to identify a novel prognostic biomarker, facilitating treatment selection, using mass spectrometry (MS)-based proteomic analysis with formalin-fixed paraffin-embedded (FFPE) tissue. The two groups with poor prognosis (n = 4) and with better prognosis (n = 4) had been carefully chosen among 96 resected cases of pancreatic cancer during 1998 to 2007 in Tohoku University Hospital. Although those 2 groups had adjusted background (UICC-Stage IIB, Grade2, R0, gemcitabine adjuvant), there was a significant difference in postoperative mean survival time (poor 21.0 months, better 58.1 months, P = 0.0067). Cancerous epithelial cells collected from FFPE tissue sections by laser micro-dissection (LMD) were processed for liquid chromatography-tandem mass spectrometry (LC-MS/MS). In total, 1099 unique proteins were identified and 6 proteins showed different expressions in the 2 groups by semi-quantitative comparison. Among these 6
A pancreatic adenocarcinoma cell line (Paca44) was treated with trichostatin-A (TSA), a potent inhibitor of histone deacetylases, in order to evaluate the effect of this drug on protein expression. Master maps of control and treated Paca44 cells were generated by analysis with the PDQuest software. The comparison between such maps showed up- and downregulation of 51 polypeptide chains, out of a total of 700 spots detected by a medium-sensitivity stain, micellar Coomassie Brilliant Blue. Fingerprinting by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF)-mass spectrometry analysis enabled the identification of 22 of these spots. Among these proteins, of particular interest are the two downregulated proteins nucleophosmin and translationally controlled tumor protein, as well as the upregulated proteins programmed cell death protein 5 (also designated as TFAR19) and stathmin (oncoprotein 18). The modulation of these four proteins is consistent with our observation that TSA is ...
BACKGROUND: Characterization of molecular mechanisms underpinning development of pancreatic ductal adenocarcinoma (PDAC) may lead to the identification of novel therapeutic targets and biomarkers. SgK223, also known as Pragmin, is a pseudokinase and scaffolding protein closely related to SgK269/PEAK1. Both proteins are implicated in oncogenic tyrosine kinase signaling, but their mechanisms and function remain poorly characterized. METHODS: Expression of SgK223 in PDAC and PDAC cell lines was characterized using gene expression microarrays, mass spectrometry (MS)-based phosphoproteomics and Western blotting. SgK223 was overexpressed in human pancreatic ductal epithelial (HPDE) cells via retroviral transduction, and knocked down in PDAC cells using siRNA. Cell proliferation was determined using a colorimetric cell viability assay, and cell migration and invasion using transwells. Expression of markers of epithelial-mesenchyme transition (EMT) was assayed by quantitative PCR. SgK223 and Stat3 signaling was
Development of systems that reconstitute hallmark features of human pancreatic intraepithelial neoplasia (PanINs), the precursor to pancreatic ductal adenocarcinoma, could generate new strategies for early diagnosis and intervention. However, human cell-based PanIN models with defined mutations are unavailable. Here, we report that genetic modification of primary human pancreatic cells leads to development of lesions resembling native human PanINs. Primary human pancreas duct cells harbouring oncogenic KRAS and induced mutations in CDKN2A, SMAD4 and TP53 expand in vitro as epithelial spheres. After pancreatic transplantation, mutant clones form lesions histologically similar to native PanINs, including prominent stromal responses. Gene expression profiling reveals molecular similarities of mutant clones with native PanINs, and identifies potential PanIN biomarker candidates including Neuromedin U, a circulating peptide hormone. Prospective reconstitution of human PanIN development from primary cells
Pancreatic ductal adenocarcinoma (PDAC) remains amongst the most lethal human cancers. PDAC is characterized by the tumor mass containing a paucity of malignant cells in association with a large desmoplastic reaction comprised of a variety of stromal components. Sporadic PDAC oncogenesis occurs as a result of the sequential acquisition of genetic aberrations occurring in core genetic pathways. Unfortunately, the average PDAC contains a large number of genetic aberrations that are not uniform between individual cancers. The interplay between the complex genetics and stromal component may represent a significant barrier to the development of effective therapy for this disease and ultimately be an important factor in PDAC lethality. The Wnt pathway has been identified as a one of the common pathways undergoing genetic alterations in PDAC. Wnt is a complex signal transduction pathway utilizing both a b-catenin dependent (canonical) and b-catenin independent (noncanonical) signals to affect a wide array of
CINTIA ELISABETH GOMEZ LIMIA. Modulation of survival, cell cycle, resistance signaling pathways and metastatic potential by ethoxzolamide in human pancreatic ductal adenocarcinoma cell line (PANC-1). 21 mar. 2013. Masters Dissertation - Universidade Estadual de Campinas (UNICAMP). Instituto de Biologia
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, which is usually diagnosed at an advanced stage. The late disease diagnosis, the limited availability of effective therapeutic interventions and lack of robust diagnostic biomarkers, are some of the primary reasons for the dismal 5-year survival rates (∼8%) in patients with PDAC. The pancreatic cancer develops through accumulation of a series of genomic and epigenomic alterations which lead to the transformation of normal pancreatic epithelium into an invasive carcinoma - a process that can take up to 15-20 years to develop, from the occurrence of first initiating mutational event. These facts highlight a unique window of opportunity for the earlier detection of PDAC, which could allow timely disease interception and improvement in the overall survival outcomes in patients suffering from this fatal malignancy. Non-coding RNAs (ncRNAs) have been recognized to play a central role in PDAC pathogenesis and are emerging ...
Background Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer worldwide, as a result of a late diagnosis and limited therapeutic options. Tumour microenvironment (or stroma) plays a key role in cancer onset and progression and constitutes an intrinsic histological hallmark of PDAC. Thus we hypothesised that relevant prognostic biomarkers and therapeutic targets can be identified in the stroma. Methods Laser microdissection of the stroma from freshly frozen PDAC was combined to gene expression profiling. Protein expression of candidate biomarkers was evaluated by immunohistochemistry on tissue microarrays (n = 80 tumours) and by ELISA in plasma samples (n = 51 patients). Results A signature made of 1256 genes that significantly discriminate the stroma from the non-tumour fibrous tissue was identified. Upregulated genes were associated with inflammation and metastasis processes and linked to NF-Kappa B and TGF beta pathways. TMA analysis validated an increased expression of SFN, ADAMTS12 and CXCL3
The best treatment strategy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) remains the subject of considerable debate. This report presents a case of a 58-year-old woman with locally advanced unresectable PDAC who was treated with sequential FOLFIRINOX for 8 cycles followed by chemoradiation, and continues to show durable disease control 18 months later. The respective roles of systemic therapy and chemoradiation for locally advanced PDAC are discussed, including optimal sequencing of these modalities, recent improvements in chemotherapy, and the question of whether radiotherapy improves survival outcomes in this disease context. ...
Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants: Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions: Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures: Overall survival, recurrence, and sites of recurrence. Results: Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9
To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53(R172H) and Kras(G12D) to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disea …
The family of cyclin-dependent kinases (CDKs) has critical functions in cell cycle regulation and controlling of transcriptional elongation. Moreover, dysregulated CDKs have been linked to cancer initiation and progression. Pharmacological CDK inhibition has recently emerged as a novel and promising approach in cancer therapy. This idea is of particular interest to combat pancreatic ductal adenocarcinoma (PDAC), a cancer entity with a dismal prognosis which is owed mainly to PDACs resistance to conventional therapies. Here, we review the current knowledge of CDK biology, its role in cancer and the therapeutic potential to target CDKs as a novel treatment strategy for PDAC ...
Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumours with dismal prognosis. Although curative resection with adjuvant chemoradiotherapy is the most effective treatment, the
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with an overall five-year survival rate of 8%. Due to subtle texture changes of PDAC, pancreatic dual-phase imaging is...
TY - JOUR. T1 - The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. AU - Peretti, U. AU - Zanon, Silvia. AU - Reni, M. PY - 2017. Y1 - 2017. N2 - No abstract available. AB - No abstract available. U2 - 10.4103/eus.eus_62_17. DO - 10.4103/eus.eus_62_17. M3 - Article. VL - 6. SP - S66-S68. JO - Endoscopic Ultrasound. JF - Endoscopic Ultrasound. SN - 2303-9027. IS - Suppl.3. ER - ...
Cancer has historically been considered as a genetic disease. Much effort have been dedicated to search for the one mutation causing normal cells to become cancer cells. But there is one property of cancer cells that is common for all cancers and that is the shift from oxidative phosphorylation in the mitochondria to aerobic glycolysis in the cytosol. The phenomena is called the Warburg effect, and it makes it possible for cells to aerobically, in a high rate, metabolize glucose to lactate. As a side effect the levels of reactive oxygen species (ROS) in the cell increases, which alters the normal homeostatic levels. In cancer cells elevated levels of ROS can also be caused by reduced activity of antioxidants, imbalanced levels of intracellular calcium, increased activity of certain receptors, higher levels of growth factors and increased intracellular production of ROS by NADPH oxidases (NOX).. PhD-project, Heléne Lindholm: NOX, ROS and metabolism in Pancreatic Ductal Adenocarcinoma. ...
Background Pancreatic ductal adenocarcinoma frequently recurs despite curative surgical resection. This study aims to investigate the patterns of recu..
Patterns and Determinants of Recurrence for Pancreatic Ductal Adenocarcinoma after Resection, Sia Kim, Malinda Itchins, Jennifer Arena, Chris Nahm, Nick
Enhancement parameters of contrast-enhanced computed tomography for pancreatic ductal adenocarcinoma: Correlation with pathologic grading
Chronic pancreatitis increases by 16 fold the risk of developing pancreatic ductal adenocarcinoma (PDAC), one of the deadliest human cancers. Activating Kras mutations have been detected in 30% of early pancreatic intraepithelial neoplasias (PanINs), increasing to 100% in advanced pancreatic ductal adenocarcinoma (PDAC).. We hypothesize that inflammatory cells recruited to the pancreas in response to chronic injury can interact with epithelial cells harboring activated KrasG12D and affect the progression of PanIN lesions. To test this hypothesis, we have used the inducible transgenic Mist1:CreERT2; LSL-KrasG12D (KCiMist1) adult mice in which the LSL KrasG12D allele is activated specifically in the acinar compartment. This model leads to rapid formation of PanINs with a classic ductal phenotype and the progression of lesions is further accelerated with the induction of chronic pancreatitis (CP) generated by recurrent injections of cerulein.. We have found that TH17 cells, a subtype of CD4+ ...
TY - JOUR. T1 - Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. AU - Herman, Joseph M.. AU - Fan, Katherine Y.. AU - Wild, Aaron T.. AU - Hacker-Prietz, Amy. AU - Wood, Laura D.. AU - Blackford, Amanda L.. AU - Ellsworth, Susannah. AU - Zheng, Lei. AU - Le, Dung T.. AU - De Jesus-Acosta, Ana. AU - Hidalgo, Manuel. AU - Donehower, Ross C.. AU - Schulick, Richard D.. AU - Edil, Barish H.. AU - Choti, Michael A.. AU - Hruban, Ralph H.. AU - Pawlik, Timothy M.. AU - Cameron, John L.. AU - Laheru, Daniel A.. AU - Wolfgang, Christopher L.. PY - 2013/7/15. Y1 - 2013/7/15. N2 - Purpose: Long-term survival rates for patients with resected pancreatic ductal adenocarcinoma (PDAC) have stagnated at 20% for more than a decade, demonstrating the need to develop novel adjuvant therapies. Gemcitabine- erlotinib therapy has demonstrated a survival benefit for patients with metastatic PDAC. Here we report the first phase 2 study of ...
Pancreatic cancer is lethal, as it is often detected late. Thus, novel biomarkers of precursor lesions are needed to devise timely therapies. Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) are major precursors of pancreatic cancer. In normal gastric mucosa, gastric gland mucin-specific O-glycans are unique in having α1,4-linked N-acetylglucosamine (αGlcNAc) residues attached to MUC6. Recently we reported that αGlcNAc functions as a tumor suppressor for differentiated-type gastric adenocarcinoma (Karasawa et al., J Clin Invest 122, 923, 2012). MUC6 is also expressed in pancreatic neoplasms, including PanIN and IPMN, but the role of αGlcNAc expression in pancreatic neoplasms remains unknown. Here, we analyze expression patterns of αGlcNAc, MUC6 and MUC5AC in pancreatic neoplasms and compare them with progression from PanIN to invasive ductal adenocarcinoma (IDAC) (the PanIN-IDAC sequence; 20 cases) and from IPMN to IPMN with associated invasive
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Thus far, most drugs have failed to significantly improve patient survival. N6-methyladenosine (m6A) plays an important role in the progression of PDAC, but its aberrant regulation driven by germline variants in human diseases remains unclear.We first performed an exome-wide association analysis in 518 PDAC patients with overall survival and replicated in an independent population containing 552 PDAC patients. Then, a series of biochemical experiments in vitro and in vivo were conducted to investigate potential mechanisms of the candidate variant and its target gene PIK3CB underlying the PDAC progression. Moreover, the PIK3CB-selective inhibitor KIN-193 was used to block PDAC tumour growth.We identified a missense variant rs142933486 in PIK3CB that is significantly associated with the overall survival of PDAC by reducing the PIK3CB m6A level, which facilitated its mRNA and protein expression levels mediated by ...
Introduction IPMN is characterized by a predominantly noninvasive growth pattern with mucin production and cystic duct dilatation. The distinction between IPMN and pancreatic intraepithelial neoplasia (PanIN) ,which is the common precursor of invasive carcinomas
There is a lack of well-established clinical tools for predicting dendritic cell (DC) vaccination response of pancreatic ductal adenocarcinoma (PDAC). DC vaccine treatment efficiency was demonstrated using histological analysis in pre-clinical studies; however, its usage was limited due to invasiveness. In this study, we aimed to investigate the potential of MRI texture features for detection of early immunotherapeutic response as well as overall survival (OS) of PDAC subjects following dendritic cell (DC) vaccine treatment in LSL-KrasG12D;LSL-Trp53R172H;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic ductal adenocarcinoma (PDAC). KPC mice were treated with DC vaccines, and tumor growth was dynamically monitored. A total of a hundred and fifty-two image features of T2-weighted MRI images were analyzed using a kernel-based support vector machine model to detect treatment effects following the first and third weeks of the treatment. Moreover, univariate analysis was performed to describe the
There is a lack of well-established clinical tools for predicting dendritic cell (DC) vaccination response of pancreatic ductal adenocarcinoma (PDAC). DC vaccine treatment efficiency was demonstrated using histological analysis in pre-clinical studies; however, its usage was limited due to invasiveness. In this study, we aimed to investigate the potential of MRI texture features for detection of early immunotherapeutic response as well as overall survival (OS) of PDAC subjects following dendritic cell (DC) vaccine treatment in LSL-KrasG12D;LSL-Trp53R172H;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic ductal adenocarcinoma (PDAC). KPC mice were treated with DC vaccines, and tumor growth was dynamically monitored. A total of a hundred and fifty-two image features of T2-weighted MRI images were analyzed using a kernel-based support vector machine model to detect treatment effects following the first and third weeks of the treatment. Moreover, univariate analysis was performed to describe the
We immunohistochemically examined material from 36 pancreata (adenocarcinomas, 30 lesions; pancreatic intraepithelial neoplasia [PanIN], 65; normal pancreatic ducts, 30) for cyclooxygenase 2 (COX-2) with an automated platform. We analyzed 7 to 10 discrete foci and generated an average percentage of …
There will be two phases to this study. The lead-in phase will evaluate the safety, pharmacokinetics, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with nab-paclitaxel and gemcitabine (nab-P + G) in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. The randomized treatment phase will evaluate the efficacy, safety, and tolerability of nab-P + G with either MMB administered at the MTD or placebo in adults with previously untreated metastatic pancreatic ductal adenocarcinoma. Participants will continue study treatment until disease progression, unacceptable toxicity, consent withdrawal, or participants refusal of treatment. Following treatment, participants will be followed for safety for 30 days and for survival approximately every 3 months for up to 3 years ...
BACKGROUND & AIMS: Small nucleolar noncoding RNAs (snoRNAs) regulate function of ribosomes, and specific snoRNAs are dysregulated in some cancer cells. We investigated dysregulation of snoRNAs in pancreatic ductal adenocarcinoma (PDAC) cells. METHODS: We investigated snoRNA expression in PDAC cell lines by complementary DNA microarray and quantitative reverse transcription polymerase chain reaction. In PDAC (n = 133), intraductal papillary mucinous neoplasm (n = 16), mucinous cystic neoplasm-associated PDAC (n = 1), and non-tumor pancreas (n = 8) and liver (n = 3) tissues from subjects who underwent surgical resection, levels of snoRNA were measured by quantitative reverse transcription polymerase chain reaction and compared with clinicopathologic parameters and survival times determined by Kaplan-Meier analysis ...
BACKGROUND: The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. METHODS: In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation. RESULTS: The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8
Depending on the cellular context, transforming growth factor β (TGFβ) has been observed to exert protumorigenic functions, such as inducing an epithelial-mesenchymal transition (EMT), or inhibit tumorigenesis by activating apoptosis. The proapoptotic functions of TGFβ have been linked with the transcription factor SMAD4, which acts downstream of TGFβ and is frequently deleted in pancreatic ductal carcinoma (PDAC). To elucidate the mechanism by which TGFβ promotes apoptosis, David and colleagues used a Kras-mutant/Smad4-deleted PDAC murine model and found that reintroduction of SMAD4 sensitized cells to TGFβ treatment and promoted changes in cell morphology and loss of E-cadherin consistent with EMT. Moreover, SNAIL was shown to be upregulated following TGFβ treatment, and genetic depletion of SNAIL inhibited TGFβ-induced EMT, apoptosis, and accelerated pancreatic carcinogenesis in SMAD4-wild-type cells, raising the unexpected possibility that EMT precedes apoptosis and is required for ...
Intraductal papillary mucinous neoplasm (IPMN) is a type of tumor that can occur within the cells of the pancreatic duct. IPMN tumors produce mucus, and this mucus can form pancreatic cysts. Although intraductal papillary mucinous neoplasms are benign tumors, they can progress to pancreatic cancer. As such IPMN is viewed as a precancerous condition. Once an intraductal papillary mucinous neoplasm has been found, the management options include close monitoring and pre-emptive surgery.[medical citation needed] Pathologists classify intraductal papillary mucinous neoplasms (IPMNs) into two broad groups - those that are associated with an invasive cancer and those that are not associated with an invasive cancer. This separation has critical prognostic significance. Patients with a surgically resected intraductal papillary mucinous neoplasm without an associated invasive cancer have an excellent prognosis (>95% will be cured), while patients with a surgically resected intraductal papillary mucinous ...
TY - JOUR. T1 - Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to a better prognosis. AU - Nakata, Kohei. AU - Ohuchida, Kenoki. AU - Aishima, Shinichi. AU - Sadakari, Yoshihiko. AU - Kayashima, Tadashi. AU - Miyasaka, Yoshihiro. AU - Nagai, Eishi. AU - Mizumoto, Kazuhiro. AU - Tanaka, Masao. AU - Tsuneyoshi, Masazumi. AU - Oda, Yoshinao. PY - 2011/5/1. Y1 - 2011/5/1. N2 - Objectives: Although intestinal-type intraductal papillary mucinous carcinoma (IPMC) is reported to have a better prognosis, few studies have addressed its invasive pattern. The meaning of minimal invasion (MI) in IPMC also remains unclear. We investigated the prognosis of intraductal papillary mucinous neoplasm (IPMN) focusing on MI and subtypes. Methods: We evaluated 71 patients with IPMC among a total of 179 patients with resected IPMN. Results: Although 2 of 10 MI-IPMC patients had lymph ...
TY - JOUR. T1 - Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?. AU - He, Jin. AU - Cameron, John L.. AU - Ahuja, Nita. AU - Makary, Martin A.. AU - Hirose, Kenzo. AU - Choti, Michael A.. AU - Schulick, Richard D.. AU - Hruban, Ralph H.. AU - Pawlik, Timothy M.. AU - Wolfgang, Christopher L.. PY - 2013/4. Y1 - 2013/4. N2 - Background: Little is known about the risk of subsequently developing a new or progressive intraductal papillary mucinous neoplasm (IPMN) after partial pancreatic resection of a noninvasive IPMN. Study Design: One hundred thirty patients with more than 1 year of follow-up after resection were included in this analysis. Results: At a median follow-up of 38 months, 22 (17%) developed imaging evidence of a new or progressive IPMN. Eleven (8%) underwent completion resection. Three of the 11 patients had invasive adenocarcinoma. Two other patients developed metastatic pancreatic adenocarcinoma and did not undergo ...
TY - JOUR. T1 - Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade. AU - Yip-Schneider, Michele T.. AU - Simpson, Rachel. AU - Carr, Rosalie A.. AU - Wu, Huangbing. AU - Fan, Hao. AU - Liu, Ziyue. AU - Korc, Murray. AU - Zhang, Jianjun. AU - Schmidt, C. Max. PY - 2019/5/15. Y1 - 2019/5/15. N2 - Background: The most common type of mucinous pancreatic cyst that may progress to pancreatic cancer is intraductal papillary mucinous neoplasm (IPMN). Low-risk IPMN with low-/moderate-grade dysplasia may be safely watched, whereas high-risk IPMN with high-grade dysplasia or invasive components should undergo resection. However, there is currently no reliable means of making this distinction. We hypothesize that blood concentrations of insulin resistance biomarkers may aid in the differentiation of low- and high-risk IPMN. Methods: Plasma/serum was collected from consented patients undergoing pancreatic resection. IPMN diagnosis and ...
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity.: Intraductal papillary mucinous neoplasms represe
Expression of MUC4 Mucin Is Observed Mainly in the Intestinal Type of Intraductal Papillary Mucinous Neoplasm of the PancreasExpression of MUC4 Mucin Is Observed Mainly in the Intestinal Type of Intraductal Papillary Mucinous Neoplasm of the Pancreas ...
Answer: Intraductal Papillary Mucinous Neoplasm. Histology: This papillary mucin-producing neoplasm involved a branch duct off of the main pancreatic duct. The main pancreatic duct was not involved. Ovarian stroma was not present.. Discussion: Intraductal papillary mucinous neoplasms (IPMNs) are characterized by involvement by one of the larger pancreatic ducts and by the presence of a papillary mucin-producing epithelium without associated ovarian-type stroma. Intraductal papillary mucinous neoplasms can be subcategorized into those which involve the main pancreatic duct and those which involve a branch of the main pancreatic duct. In this case, this intraductal papillary mucinous neoplasm did not involve the main pancreatic duct, but rather involved a branch duct. It is therefore a branch duct IPMN. The most important prognosticator for patients with intraductal papillary mucinous neoplasms is the presence or absence of an associated invasive carcinoma. In addition, it has been suggested that ...
We have previously shown that WW domain-containing oxidoreductase (WWOX) has tumour-suppressing effects and that its expression is frequently reduced in pancreatic carcinoma. In this study, we examined WWOX expression in intraductal papillary mucinous neoplasm of the pancreas (IPMN) to assess the function of WWOX in pancreatic duct tumourigenesis using immunohistochemistry and methylation-specific polymerase chain reaction analysis. Among 41 IPMNs including intraductal papillary mucinous adenomas (IPMAs) and intraductal papillary mucinous carcinomas (IPMCs), loss or reduced WWOX immunoreactivity was detected in 3 (15%) of 20 IPMAs and 17 (81%) of 21 IPMCs. In addition, hypermethylation of the WWOX regulatory site was detected in 1 (33%) of 3 WWOX(−) IPMAs and 9 (53%) of 17 WWOX(−) IPMCs, suggesting that hypermethylation may possibly be important in the suppression of WWOX expression. Reduction of WWOX expression was significantly correlated with a higher Ki-67 labelling index but was not correlated
Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Kloppel G, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Shimizu M, Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004 Aug;28(8):977-87 ...
ASA 2018 Abstracts: Does Surgical Margin Impact Recurrence in Non-Invasive Intraductal Papillary Mucinous Neoplasms? A Multi-Institutional Study
article{41680afa-1eab-45c3-aa76-62b426b1b7aa, author = {Ansari, Daniel and Aronsson, Linus and Andersson, Roland}, issn = {1479-6694}, keyword = {biomarkers,gastrointestinal,molecular oncology,oncogenes,pancreatic biliary,surgery}, language = {eng}, month = {08}, number = {20}, pages = {1751--1753}, publisher = {Future Medicine Ltd.}, series = {Future Oncology}, title = {Biomarkers, imaging and multifocality in intraductal papillary mucinous neoplasms : Relevant for decision making?}, url = {}, volume = {13}, year = {2017 ...
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC). Therefore, we investigated the prognostic significance of GFPT1 expression in patients with resectable PDAC. We analyzed public datasets to compare GFPT1 expression in tumor tissues and normal/adjacent pancreatic tissues. We measured the relative GFPT1 expression of 134 resected PDAC specimens in our institution, using real-time polymerase chain reaction (PCR). Survival was compared between high and low GFPT1 expression groups using Kaplan-Meier curves and log-rank tests. Multivariate analyses were estimated using Cox regression and logistic regression models. GFPT1 is generally upregulated in PDAC tissues, according to the analysis of public datasets. The data from our institution shows that high GFPT1 expression was correlated with a high rate of lymph node (LN) metastasis (p = 0
Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach. Here we investigated the concordance between mutations found in the primary tumor and pancreatic juice from the same patient. Amplicon-based targeted deep sequencing was performed on samples from 21 patients with pancreatic ductal adenocarcinoma (PDAC) who had undergone Whipples operation. Mutation profiles were determined in formalin-fixed sections of the primary tumor and in pancreatic juice sampled from the main pancreatic duct during surgery. Using a cut-off of 3% for variant allele frequency, KRAS mutations were detected in 20/21 primary tumors (95%) and in 15/21 (71%) juice samples. When also considering low-frequency variants, KRAS mutations were found in 20/21 juice samples. Most juice samples exhibited multiple KRAS variants not seen in the primary tumor, and only in 11 cases (52%
BACKGROUND: Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC). However, analysis of prognostic factors is limited for patients with PDAC treated with neoadjuvant chemoradiation and pancreaticoduodenectomy (PD). METHODS: The study population was comprised of 240 consecutive patients with PDAC who received neoadjuvant chemoradiation and PD and was compared with 60 patients who had no neoadjuvant therapy between 1999 and 2007. Clinicopathologic features were correlated with disease-free survival (DFS) and overall survival (OS). RESULTS: Among the 240 treated patients, the 1-year and 3- year DFS rates were 52% and 32%, with a median DFS of 15.1 months. The 1-year and 3-year OS rates were 95% and 47%, with a median OS of 33.5 months. By univariate analysis, DFS was associated with age, post-therapy tumor stage (ypT), lymph node status (ypN), number of positive lymph nodes, and American Joint Committee on Cancer (AJCC) stage, ...
TY - JOUR. T1 - Laparoscopic Pancreaticoduodenectomy. Is It an Effective Procedure for Pancreatic Ductal Adenocarcinoma?. AU - Tee, May C.. AU - Kendrick, Michael L.. AU - Farnell, Michael B.. PY - 2015/9/1. Y1 - 2015/9/1. KW - Laparoscopic pancreaticoduodenectomy/Whipple procedure. KW - Oncologic outcomes. KW - Technical safety. UR - UR - U2 - 10.1016/j.yasu.2015.03.003. DO - 10.1016/j.yasu.2015.03.003. M3 - Review article. C2 - 26299496. AN - SCOPUS:84983127113. VL - 49. SP - 143. EP - 156. JO - Advances in Surgery. JF - Advances in Surgery. SN - 0065-3411. IS - 1. ER - ...
Despite expression of oncogenic KRAS, premalignant pancreatic intraepithelial neoplasia 1 (PanIN1) lesions rarely become fully malignant pancreatic ductal adenocarcinoma (PDAC). The molecular mechanisms through which established risk factors, such as chronic pancreatitis, acinar cell damage, and/or defective autophagy increase the likelihood of PDAC development are poorly understood. We show that accumulation of the autophagy substrate p62/SQSTM1 in stressed KrasG12D acinar cells is associated with PDAC development and maintenance of malignancy in human cells and mice. p62 accumulation promotes neoplastic progression by controlling the NRF2-mediated induction of MDM2, which acts through p53-dependent and -independent mechanisms to abrogate checkpoints that prevent conversion of differentiated acinar cells to proliferative ductal progenitors. MDM2 targeting may be useful for preventing PDAC development in high-risk individuals ...
Intraductal tubular adenoma of the pancreas, pyloric gland type (ITA), is an infrequent intraductal benign lesion located in the main duct and large branch duct of the pancreas. The purpose of this report is to introduce seven new cases and to compare their clinicopathologic features and KRAS mutations to gastric-type intraductal papillary mucinous neoplasms (IPMNs) and intraductal tubulopapillary neoplasms (ITPNs). Clinical findings, morphologic features, immunophenotypes and KRAS alterations were investigated in 7 patients with intraductal tubular adenomas, 16 patients with gastric-type intraductal papillary mucinous neoplasms and 6 patients with intraductal tubulopapillary neoplasms. There were more female patients in the ITA and gastric-type IPMN groups, whereas the opposite pattern was observed in the ITPN group. ITAs and gastric-type IPMNs were lined by columnar cells, similar to pyloric glands, with large extracellular deposits of mucin. ITPNs were polypoid and papillary mass located in the
Autori: Lefter LP, Sunamura M, Furukawa T, Yastsuoka T, Abe H, Inoue H, Abe T, Egawa S, Miura K, Morita R, Horii A, Matsuno S.. Editorial: Asian J Surg. 2004 Apr;27(2):85-92., 2004.. Rezumat:. BACKGROUND: In a previous work, we demonstrated that loss of heterozygosity of 18q is a frequent event significantly associated with poor prognosis in pancreatic cancer. We hypothesized that restoration of heterozygosity of chromosome 18 in pancreatic cancer cells would reduce their tumorigenicity. This study was intended to provide functional evidence for the existence of new tumour suppressor gene(s) located on chromosome 18. METHOD: Restoration of heterozygosity was achieved by introducing a normal copy of chromosome 18 into pancreatic ductal carcinoma using a microcell-mediated chromosome transfer technique. The tumorigenicity and metastatic ability of both the parental cells and resulting hybrids were assessed in vitro and in vivo. RESULTS: In vitro growth of hybrid clones was significantly delayed ...
An ASCO clinical practice guideline update, reported by Khorana et al in the Journal of Clinical Oncology, includes the recommendation of gemcitabine-capecitabine doublet therapy as an adjuvant therapy option in potentially curable pancreatic cancer. The updated recommendation (4.1) modifies the corresponding recommendation in the ASCO guideline published in May 2016. The remaining recommendations from the original 2016 ASCO guideline are unchanged.. New Evidence. The ASCO guideline expert panel based the update on findings in the recently reported phase III ESPAC-4 study, in which 730 evaluable patients with resected pancreatic ductal adenocarcinoma were randomized to receive gemcitabine plus capecitabine or gemcitabine alone. Median overall survival was 28.0 months in the doublet group vs 25.5 months in the gemcitabine-alone group (hazard ratio = 0.82, P = .032). Grade 3 and 4 adverse events were similar in both groups, although the doublet group had higher rates of hand-foot syndrome and ...
1240 The epidermal growth factor receptor (EGFR) is overexpressed in up to 60% of pancreatic cancer specimens. Recently, erlotinib (a small-molecule tyrosine kinase inhibitor, TKI) was approved for pancreatic cancer treatment. There is an association between TKI response in non-small cell lung cancer (NSCLC) and specific activating mutations in the EGFR tyrosine kinase (TK) domain. The applicability of this paradigm in pancreatic cancer was analyzed by evaluating the presence of activating EGFR TK mutations and EGFR pathway activation in a large cohort of pancreatic adenocarcinoma patients. Pancreatic adenocarcinoma is characterized by an exuberant desmoplastic reaction, masking precise analysis of tumor cells. State-of-the-art laser capture microdissection (LCM) allowed us to selectively isolate pancreatic ductal adenocarcinoma cells from their surrounding stromal elements. DNA, protein, and mRNA were extracted from 30 human frozen pancreatic cancer specimens following LCM of tissue sections ...
TY - JOUR. T1 - Culture and immortalization of pancreatic ductal epithelial cells.. AU - Lawson, Terence. AU - Ouellette, Michel M. AU - Kolar, Carol. AU - Hollingsworth, Michael A. PY - 2005. Y1 - 2005. N2 - Some populations of the epithelial cells from the duct and ductular network of the mammalian pancreas have been isolated and maintained in vitro for up to 3 mo. These cells express many of the surface factors that are unique to them in vivo. They also retain significant drug- and carcinogen-metabolizing capacity in vitro. In this chapter we review the progression of the methods for the isolation, culture and maintenance in vitro for these cells from the earliest when only duct/ductular fragments were obtainable to the current ones which provide epithelial cells. The critical steps in the isolation process are identified and strategies are provided to facilitate these steps. These include the selection of tissue digestive enzymes, the importance of extensive mincing before culture and the ...
The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1-Stat3 signaling. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Pancreatic ductal adenocarcinoma (PDAC) offers an optimal model for discovering « druggable » molecular pathways that participate in inflammation-associated cancer development. Chronic pancreatitis, a common prolonged inflammatory disease, behaves as a well-known premalignant condition that contributes to PDAC development. Although the mechanisms underlying the pancreatitis-to-cancer transition remain to be fully elucidated, emerging evidence supports the hypothesis that the actions of proinflammatory mediators on cells harboring Kras mutations promote neoplastic transformation. Recent elegant studies demonstrated that the IL17 pathway mediates this phenomenon and can be targeted with antibodies, but the downstream mechanisms by which IL17 functions during this transition are currently unclear. In this study, we demonstrate that IL17 induces the expression of REG3β, a well-known mediator of pancreatitis, during acinar-to-ductal metaplasia and in early pancreatic intraepithelial neoplasia ...
Like weeds sprouting from cracks in the pavement, cancer often forms in sites of tissue damage. That damage could be an infection, a physical wound, or some type of inflammation. Common examples include stomach cancer caused by H. pylori infection, Barretts esophagus caused by acid reflux, and even smoking-induced lung cancer.. Exactly how tissue damage colludes with genetic changes to promote cancer isnt fully understood. Most of what scientists know about cancer concerns advanced stages of the disease. Thats especially true for cancers such as pancreatic cancer that are usually diagnosed very late.. Researchers in Scott Lowes lab at the Sloan Kettering Institute are now trying to zero in on the earliest stages of pancreatic cancer development.. If we understood how these tumors form, maybe we could catch them before the cancer has progressed to an incurable stage, says Direna Alonso Curbelo, a postdoctoral fellow in the Lowe lab who is the first author of a new paper published February 3 ...
Intraductal papillary mucinous neoplasm (IPMN), the most common pancreatic cystic neoplasm, is known to progress to invasive ductal adenocarcinoma. IPMNs commonly harbor activating somatic mutations in GNAS and KRAS, primarily GNAS(R201H) and KRAS(G12D). GNAS encodes the stimulatory G-protein α subunit (Gsα) that mediates a stimulatory signal to adenylyl cyclase to produce cyclic adenosine monophosphate (cAMP), subsequently activating cAMP-dependent protein kinase A. The GNAS(R201H) mutation results in constitutive activation of Gsα. To study the potential role of GNAS in pancreatic tumorigenesis in vivo, we generated lines of transgenic mice in which the transgene consisted of Lox-STOP-Lox (LSL)-GNAS(R201H) under the control of the CAG promoter (Tg(CAG-LSL-GNAS)). These mice were crossed with pancreatic transcription factor 1a (Ptf1a)-Cre mice (Ptf1a(Cre/+)), generating Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) mice. This mouse line showed elevated cAMP levels, small dilated tubular complex formation, ...
TY - JOUR. T1 - Long-term surgical outcome of noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma of the pancreas. AU - Nakagohri, Toshio. AU - Asano, Takehide. AU - Kenmochi, Takashi. AU - Urashima, Tetsuro. AU - Ochiai, Takenori. PY - 2002/9/1. Y1 - 2002/9/1. N2 - The objective of this study was to clarify the long-term outcome after surgical resection in patients with noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma. We performed a retrospective review of the clinicopathological features and outcome in patients who underwent pancreatic resection for noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma between November 1982 and December 1997 at Chiba University Hospital. Minimally invasive structures were pathologically observed in five cases. The mean age of patients with either noninvasive (n = 16) or minimally invasive (n = 5) adenocarcinoma was 61 years. Of the patients with minimally invasive ...
As reported by Vasen et al in the Journal of Clinical Oncology, surveillance for pancreatic ductal adenocarcinoma in high-risk individuals appears to be of benefit in individuals at risk due to CDKN2A mutation, with the advantage being less clear among individuals at risk due to familial clustering of pancreatic cancer.. Study Details. The study was a long-term prospective follow-up from three European expert centers. A total of 411 asymptomatic individuals, including 178 CDKN2A mutation carriers, 214 individuals with familial pancreatic cancer, and 19 BRCA1/2 or PALB2 mutation carriers, participated in a surveillance program consisting of annual magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography, or endoscopic ultrasound (EUS).. Individuals had a mean age of 56 years at the start of the program, and mean follow-up was 53 months (range = 0-169 months). In total, 866 MRIs and 106 EUSs were performed.. Surveillance Outcome. Pancreatic ductal adenocarcinoma was detected ...
Background Pancreatic ductal adenocarcinoma (PDAC) patients have the poorest 5-year survival rates of all cancer forms. It is difficult to diagnose at early disease stages, tumour relapse after surgery is common, and current chemotherapies are ineffective. Carbohydrate antigen 19-9 (Ca 19-9), the only clinically implemented PDAC biomarker, is insufficient for diagnostic and screening purposes.. PDAC tumours are characterised by a voluminous stroma that is rich in extracellular matrix (ECM) molecules such as collagens, hyaluronan (HA) and matricellular proteins. These stromal components have been suggested to promote PDAC cell migration, proliferation, evasion of apoptosis and chemotherapy resistance. Those events are mediated via interactions with adhesion receptors, such as integrins and CD44 receptors expressed on cancer cell surfaces.. Micro-RNAs (miRNA) post-transcriptionally regulate gene expression in health and disease. At the time of PDAC diagnosis, miRNA levels are altered both in ...
Mammalian target of rapamycin complicated 1 (mTORC1) is generally activated in individual cancers; however scientific studies of rapalog (the mTORC1 inhibitors) show that pancreatic ductal adenocarcinomas (PDACs) withstand to the procedure. overcome rapalog level of resistance in PDAC. and N-genes. K-or N-mutations play a crucial function in the rapalog level of resistance in PDAC. K-mutations donate to the rapalog-induced reviews activation of IGF-1-Ras-Raf-ERK pathway and inhibition from the mt K-Ras abolishes the reviews ERK signal decreases the rapalog level of resistance and therefore enhance inhibitory aftereffect of rapalog over the development of K-Ras mt PDAC cells-derived mouse xenografts. 2 Components and Strategies 2.1 Individual pancreatic carcinoma cell lines tissue and regular pancreatic tissues Individual PDAC cell lines BxPC-3 Capan-2 Hs 766T and PANC-1 had been extracted from the American Type Lifestyle Collection (Rockville MD). BxPC-3 was harvested in RPMI-1640 moderate ...
Burmi R, Maginn E, Gabra H, Stronach E, Wasan Het al., 2019, Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-2-regulated apoptosis in pancreatic cancer cells, Cancer Biology and Therapy, Vol: 20, Pages: 21-30, ISSN: 1555-8576 Pancreatic ductal adenocarcinoma (PDAC) progression and chemotherapy insensitivity have been associated with aberrant PI3K/mTOR/MEK signalling. However, cell death responses activated by inhibitors of these pathways can differ - contextually varying with tumour genetic background. Here, we demonstrate that combining the dual PI3K/mTOR inhibitor PF5212384 (PF384) and MEK inhibitor PD325901 (PD901) more effectively induces apoptosis compared with either agent alone, independent of KRAS mutational status in PDAC cell lines. Additionally, a non-caspase dependent decrease in cell viability upon PF384 treatment was observed, and may be attributed to autophagy and G0/G1 cell cycle arrest. Using reverse phase protein arrays, we identify key molecular events ...
exocrine pancreatic cancer, pancreatic adenocarcinomas, pancreatic cancer; pancreas cancer Digital case JRC:10443 : cutaneous metastasis of a (...)
BACKGROUND: Intraductal papillary mucinous neoplasms (IPMNs) are non-invasive precursor lesions of pancreatic cancer. Misexpression of microRNAs (miRNAs) is commonly observed in pancreatic adenocarcinoma. In contrast, miRNA abnormalities in pancreatic cancer precursor lesions have not been documented.. EXPERIMENTAL DESIGN: Relative expression levels of a panel of twelve miRNAs upregulated in pancreatic cancers were assessed in 15 non-invasive IPMNs, using quantitative reverse transcription PCR (qRT-PCR). Two significantly overexpressed miRNAs-miR-155 and miR-21-were evaluated by locked nucleic acid in situ hybridization (LNA-ISH) in a panel of 64 archival IPMNs. The expression of miR-155 and miR-21 was also evaluated in pancreatic juice samples obtained from ten patients with surgically resected IPMNs and five patients with non-neoplastic pancreato-biliary disorders (disease controls).. RESULTS: Significant overexpression by qRT-PCR of ten of the twelve miRNAs was observed in the 15 IPMNs ...
The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis.. Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma.. In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients medical records as well as assessing the histological sections and performing immunohistochemical staining for p63. ...
PD‐L1 plays a central role in permitting cancer evasion, mainly by interfering with T‐cell functions, and inhibitors of the PD‐1/PD‐L1 axis have changed the paradigm in the management of melanoma patients (Clark et al, 2007). However, PDAC is characterized by a highly immunosuppressive stroma (Hiraoka et al, 2006; Lutz et al, 2014; Beatty et al, 2015; Diana et al, 2016b; Zhang et al, 2017) and immune checkpoint inhibitors alone were ineffective in the clinical setting (Royal et al, 2010; Brahmer et al, 2012). Evidence indicates potentially complementary roles for immunotherapy and RT (Sharabi et al, 2015a), but this combination has not been explored in PDAC. Here, we show that blockade of PD‐L1 strongly enhanced tumor response to high (12, 5 × 3, and 20 Gy) but not low (6 and 5 × 2 Gy) RT doses, albeit a trend was noted for low doses. In addition to sensitizing tumors to RT, anti‐PD‐L1 improved response after gemcitabine‐based chemoradiation. This is, to our knowledge, the ...
Design We developed a computational framework to reconstruct the non-coding transcriptome from cross-sectional RNA-Seq, integrating somatic copy number alterations (SCNA), common germline variants associated to PDA risk and clinical outcome. We validated the results in an independent cohort of paired epithelial and stromal RNA-Seq derived from laser capture microdissected human pancreatic tumours, allowing us to annotate the compartment specificity of their expression. We employed systems and experimental biology approaches to interrogate the function of epithelial long non-coding RNAs (lncRNAs) associated with genetic traits and clinical outcome in PDA. ...
Authors: Pedro A Perez-Mancera, Alistair G Rust, Louise van der Weyden, Glen Kristiansen, Allen Li, Aaron L Sarver, Kevin AT Silverstein, Robert Gruetzmann, Daniela Aust, Petra Ruemmele, Thomas Knoesel, Colin Herd, Derek L Stemple, Ross Kettleborough, Jacqueline A Brosnan, Ang Li, Richard Morgan, Spencer Knight, Jun Yu, Shane Stegeman, Lara S Collier, Jelle J ten Hoeve, Jeroen de Ridder, Alison P Klein, Michael Goggins, Ralph H Hruban, David K Chang, Andrew V Biankin, Sean M Grimmond, Lodewyk FA Wessels, Stephen A Wood, Christine A Iacobuzio-Donahue, Christian Pilarsky, David A Largaespada, David J Adams, David A Tuveson
ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO or via grants from the sponsors and supporters.. Via L. Taddei 4, 6962 Viganello - Lugano - CH © Copyright 2017 European Society for Medical Oncology All rights reserved worldwide.. ...
Authors: Lindsey Stobie; Eve Karloski; Arlene Colvin; Cynthia Lim; Mary Linton Peters; Jill Krejdovsky; Kim DeLeonardis; Melissa Luna; Arthur J Moser; Kyle Allen; Virginia Speare; Jill Dolinsky; Erkut Borazanci; Nadine Tung; Randall Brand; Beth ...
Looking for branch duct? Find out information about branch duct. branch duct: installation branch duct An air duct which branches from a main duct; at this point the main duct is reduced in cross-sectional area Explanation of branch duct
The integrin αvβ6 is upregulated in numerous carcinomas, where expression commonly correlates with poor prognosis. αvβ6 promotes tumour invasion, partly through regulation of proteases and cell migration, and is also the principal mechanism by which epithelial cells activate TGF-β1; this latter function complicates therapeutic targeting of αvβ6, since TGF-β1 has both tumour-promoting and -suppressive effects. It is unclear how these different αvβ6 functions are linked; both require actin cytoskeletal reorganisation, and it is suggested that tractive forces generated during cell migration activate TGF-β1 by exerting mechanical tension on the ECM-bound latent complex. We examined the functional relationship between cell invasion and TGF-β1 activation in pancreatic ductal adenocarcinoma (PDAC) cells, and confirmed that both processes are αvβ6-dependent. Surprisingly, we found that cellular functions could be biased towards either motility or TGF-β1 activation depending on the ...
"Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma". Oncol. Rep. 20 (6): ... Hellstrom I, Hellstrom KE (2008). "SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with ... Bharadwaj U, Li M, Chen C, Yao Q (2008). "Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin ... Mesothelin is over expressed in several human tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung ...
... is a human pancreatic cancer cell line isolated from a pancreatic carcinoma of ductal cell origin. PANC-1 was derived ... 15 May 1975). "Establishment of a continuous tumor‐cell line (PANC‐1) from a human carcinoma of the exocrine pancreas". ... May 2010). "Phenotype and Genotype of Pancreatic Cancer Cell Lines". Pancreas. 39 (4): 425-435. doi:10.1097/MPA. ...
... expression analysis in human pancreatic ductal carcinomas". Genomics. 46 (2): 284-6. doi:10.1006/geno.1997.5018. PMID 9417916. ... Cattaneo M, Fontanella E, Canton C, Delia D, Biunno I (2006). "SEL1L affects human pancreatic cancer cell cycle and ...
Overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. Mice lacking Akt2 have a ... The gene was shown to be amplified and overexpressed in 2 of 8 ovarian carcinoma cell lines and 2 of 15 primary ovarian tumors ... Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR (1996). "Amplification of AKT2 in human pancreatic ... is amplified in human ovarian carcinomas". Proc Natl Acad Sci U S A. 89 (19): 9267-71. doi:10.1073/pnas.89.19.9267. PMC 50107. ...
... miR-224 has also been linked with pancreatic ductal carcinoma, where it is thought to repress CD40 expression in cancer cells. ... "Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas". Annals of Surgical ... miR-224 has been noted as the most upregulated microRNA in hepatocellular carcinoma. The same study identified a target of mir- ... "Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a ...
... ductal carcinoma of the pancreas and colorectal cancer. Several germline KRAS mutations have been found to be associated with ... Somatic KRAS mutations are found at high rates in leukemias, colorectal cancer, pancreatic cancer and lung cancer. The impact ... Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (May 1988). "Most human carcinomas of the exocrine pancreas ... Burmer GC, Loeb LA (April 1989). "Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma". ...
Poor prognosis and clinical progression of hepatocellular carcinoma, pancreatic adenocarcinoma, and colorectal cancer are all ... "Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma". Clinical ... Additionally, miRNA silencing of MAP4K4 in pancreatic beta-cells conferred protection against TNF-α repression of insulin ... pancreatic and ovarian cancer where such up-regulation is associated with increased cell migration, adhesion and invasiveness. ...
... such as non-triple negative ductal carcinoma in situ, breast cancer, pancreatic adenocarcinoma, and colorectal carcinoma. It is ... Brown J (2016). Immunohistochemical and genomic analysis of ductal carcinoma in situ of the human breast (PDF) (Ph.D.). Kings ... "FAM71E1- Pancreatic islet-like cell clusters derived from T3 embryonic stem cells". Retrieved 2018-05-07 ... Its expression is elevated prior to the differentiation of embryonic stem cells into pancreatic islet-like cells. The FAM71E1 ...
A recent study investigated the use of miRNA as a biomarker in pancreatic ductal adenocarcinoma, a form of pancreatic cancer. ... Included in the findings was an association between hepatocellular carcinoma and the upregulation of miR-92a, a member of ... The study analyzed RNA from biopsied pancreatic cysts to identify deviations in expression of miRNAs. The study found that 228 ... "Towards a clinical use of miRNAs in pancreatic cancer biopsies". Expert Rev Mol Diagn. 13 (1): 31-4. doi:10.1586/erm.12.136. ...
November 1995). "Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ ... esophageal adenocarcinoma and esophageal squamous-cell carcinoma, gastric cancer, bile duct cancer, pancreatic cancer, small ... Habuchi T (August 2005). "Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and ... January 1983). "Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes". N. ...
... ductal MeSH C04.557.470.615.132.500 - carcinoma, ductal, breast MeSH C04.557.470.615.132.750 - carcinoma, pancreatic ductal ... ductal MeSH C04.557.470. - carcinoma, ductal, breast MeSH C04.557.470. - carcinoma, pancreatic ... carcinoma, pancreatic ductal MeSH C04.588.322.455 - ovarian neoplasms MeSH C04.588.322.455.398 - granulosa cell tumor MeSH ... carcinoma, pancreatic ductal MeSH C04.588.274.780 - peritoneal neoplasms MeSH C04.588.322.078 - adrenal gland neoplasms MeSH ...
Breast Acute myeloid leukemia Pancreatic ductal adenocarcinoma Ovarian B cell lymphoma Renal cell carcinomas Lung Glioblastoma ...
... carcinoma, pancreatic ductal MeSH C19.344.609.145 - acth-secreting pituitary adenoma MeSH C19.344.609.145.500 - nelson syndrome ... carcinoma, islet cell MeSH C19.344.421.500.124 - gastrinoma MeSH C19.344.421.500.249 - glucagonoma MeSH C19.344.421.500.500 - ... carcinoma, endometrioid MeSH C19.391.630.705.398 - granulosa cell tumor MeSH C19.391.630.705.464 - luteoma MeSH C19.391.630.705 ... adrenocortical carcinoma MeSH C19.344.400.500 - multiple endocrine neoplasia type 1 MeSH C19.344.400.505 - multiple endocrine ...
... carcinoma, pancreatic ductal MeSH C06.405.117.102 - barrett esophagus MeSH C06.405.117.119 - deglutition disorders MeSH C06.405 ... carcinoma, pancreatic ductal MeSH C06.689.750.650 - pancreatitis, acute necrotizing MeSH C06.689.750.660 - pancreatitis, ... carcinoma, islet cell MeSH C06.301.761.500.124 - gastrinoma MeSH C06.301.761.500.249 - glucagonoma MeSH C06.301.761.500.500 - ... pancreatic pseudocyst MeSH C06.689.667.249 - adenoma, islet cell MeSH C06.689.667.249.500 - insulinoma MeSH C06.689.667.500 - ...
... thyroid carcinoma, bladder urothelial carcinoma - nonpapillary, uterine corpus (endometrial carcinoma), pancreatic ductal ... lung squamous cell carcinoma, kidney papillary carcinoma, clear cell kidney carcinoma, breast ductal carcinoma, renal cell ... Pancreatic cancer - Ductal adenocarcinoma and ovarian cancer - Serous cystadenocarcinoma Canada: Pancreatic cancer - Ductal ... esophageal carcinoma, ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large ...
... for metastatic small cell lung cancer Treatment of advanced or metastatic pancreatic ductal adenocarcinoma Comparison of ... aldoxorubicin and doxorubicin for patients with metastatic or locally advanced carcinoma A phase III trial for patients with ... "Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer" at ... therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic ...
... certain types of skin diseases Cancer Prostate cancer Pancreatic ductal carcinoma Cosmetic applications Facial rejuvenation ...
"Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma". Proc. Natl. Acad. Sci. U.S.A. 110 ( ... "RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian ... "Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma". Mol. Cancer ...
"Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal ... "Altered expression of members of the IGF-axis in clear cell renal cell carcinoma". Int. J. Oncol. 26 (4): 923-31. doi:10.3892/ ... pancreatic cancer, and clear cell renal cell cancer in which high tissue IGFBP-3 expression has been linked to poor prognostic ... expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma ...
Invasive ductal carcinoma: 55% of breast cancers Ductal carcinoma in situ: 13% Invasive lobular carcinoma: 5% The vast majority ... pancreas; over 80% of pancreatic cancers are ductal adenocarcinomas. prostate cancer is nearly always adenocarcinoma cervical ... Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name- ... "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004". Cancer ...
Pancreatic ductal carcinoma is a common form of pancreatic cancer. The pancreatic duct is also called the duct of Wirsung. This ... The pancreatic duct, or duct of Wirsung (also, the major pancreatic duct due to the existence of an accessory pancreatic duct ... Pancreatic duct Deep dissection.Anterior view. Ultrasonography of a dilated pancreatic duct (in this case 9mm) due to ... Most people have just one pancreatic duct. However, some have an additional accessory pancreatic duct, also called the Duct of ...
Types include: Mammary Ductal carcinoma in situ Invasive ductal carcinoma Pancreatic ductal carcinoma "NCI Dictionary of Cancer ... Ductal carcinoma is a type of tumor that primarily presents in the ducts of a gland. ... Media related to Ductal carcinomas at Wikimedia Commons v t e. ...
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ... In some types of carcinomas, Stage 0 carcinoma has been used to describe carcinoma in situ, and occult carcinomas detectable ... Breast: Nearly all breast cancers are ductal carcinoma.. *Prostate: The most common form of carcinoma of the prostate is ... Some carcinomas are named for their or the putative cell of origin, (e.g.hepatocellular carcinoma, renal cell carcinoma). ...
"FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth". International Journal ... prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma ...
... saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo". Molecular Therapy. 24 (6): 1106 ... "C/EBPα Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/β-Catenin Signaling ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ... Micrographs of normal pancreas, pancreatic intraepithelial neoplasia (precursors to pancreatic carcinoma) and pancreatic ... Other exocrine cancers include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, ... List of people diagnosed with pancreatic cancer. References[edit]. *^ a b c d e f g "Pancreatic Cancer Treatment (PDQ®) Patient ...
The most common is ductal adenocarcinoma. The most significant risk factors for pancreatic cancer are advanced age (over 60) ... Moss, AC; Morris, E; Mac Mathuna, P (Apr 19, 2006). "Palliative biliary stents for obstructing pancreatic carcinoma". The ... are more likely to be carcinomas, whilst those located below (towards the feet) are more likely to be squamous cell carcinomas ... Pancreatic cancer has a poor prognosis, with a five-year survival rate of less than 5%. By the time the cancer is diagnosed, it ...
3 May 1977). "Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma ... 17 February 2016). "MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and ... MIA PaCa-2 is a human pancreatic cancer cell line used extensively in pancreatic cancer research and therapy development. In ... MIA PaCa-2 has served for decades as a model of pancreatic cancer, and studies of MIA PaCa-2 physiology have helped clarify the ...
Liu PF, Jiang WH, Han YT, He LF, Zhang HL, Ren H (28 August 2015). "Integrated microRNA-mRNA analysis of pancreatic ductal ... In a handful of pilot studies JADE1 expression was examined in colon cancers and renal carcinomas. The results in these studies ... The human pVHL is mutated in von Hippel-Lindau hereditary disease, and in majority of sporadic clear cell renal carcinomas. ... The potential role for human JADE1 in the renewal of embryonic stem cell and embryonal carcinoma cell cultures was suggested in ...
Pancreatic cancer. Over-expression. 74%. Immunohistochemistry. [18]. Pancreatic cancer. Over-expression. 66%. ... Breast cancer (invasive ductal). Over-expression. -. Immunohistochemistry. [12]. Breast cancer (BRCA1 deficient). Over- ... Renal cell carcinoma. Under-expression. 100%. Western (protein) blotting and mRNA. [25]. ... Klopfleisch R, Schütze M, Gruber AD (Jan 2010). "RAD51 protein expression is increased in canine mammary carcinomas". ...
There is no entirely specific immunohistochemical stain that can distinguish malignant from benign biliary ductal tissue, ... Henson DE, Albores-Saavedra J, Corle D (September 1992). "Carcinoma of the extrahepatic bile ducts. Histologic types, stage of ... biliary and pancreatic tumours". Journal of Hepatology. 37 (6): 806-13. doi:10.1016/S0168-8278(02)00297-0. PMID 12445422.. ... Sugiyama M, Hagi H, Atomi Y, Saito M (1997). "Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of ...
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ... The term 'crypt cell carcinoma' has been used for them, and though perhaps more accurate than considering them carcinoids, has ... "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance ...
Ductal, lobular, and medullary. Ductal. *Ductal carcinoma in situ (DCIS): Paget's disease of the breast ... On the molecular level some similarity exists with pancreatic cancer.. Estrogen and progesterone receptor status is frequently ...
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... "Screening for Pancreatic Cancer". U.S. Preventive Services Task Force. 2004. Archived from the original on 21 November 2010.. ... An invasive ductal carcinoma of the breast (pale area at the center) surrounded by spikes of whitish scar tissue and yellow ... Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ...
"Screening for Pancreatic Cancer". U.S. Preventive Services Task Force. 2004.. *↑ Chou, Roger; Croswell, Jennifer M.; Dana, ... A large invasive ductal carcinoma in a mastectomy specimen ପ୍ରତିଷେଧସମ୍ପାଦନ କରନ୍ତୁ. କର୍କଟ ସଙ୍କଟ କମ୍ କରିବା ନିମନ୍ତେ ନିଆଯାଉଥିବା ... A squamous-cell carcinoma (the whitish tumor) near the bronchi in a lung specimen ... cervical carcinoma), ଏବସଟେନ ବାର ଭୂତାଣୁ (Epstein-Barr virus) - (ବି ସେଲ ଲିମ୍ଫୋପ୍ରୋଲିଫରେଟିଭ ରୋଗ) (B-cell lymphoproliferative ...
Ductal. *Ductal carcinoma in situ (DCIS) *Paget's disease of the breast. *Comedocarcinoma ... Between 4% and 7% of people with pancreatic cancer have a BRCA mutation.[14] However, since pancreatic cancer is relatively ... Like pancreatic cancer, it may be that only some BRCA mutations or some BRCA families have the extra risk; unlike other BRCA- ... Like prostate cancer, pancreatic cancer associated with a BRCA mutation tends to appear about a decade earlier than non- ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ...
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ... Ellison TA, Edil BH (2012). "The current management of pancreatic neuroendocrine tumors". Adv Surg (46): 283-296. PMID 22873046 ... Increased levels of somatostatin inhibit pancreatic hormones and gastrointestinal hormones. Thus somatostatinomas are ...
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ...
Ductal carcinoma(英语:Ductal carcinoma). *Mammary ductal carcinoma(英语:Mammary ductal carcinoma) ... 卵巢浆液性囊腺瘤 / Pancreatic serous cystadenoma(英语:Pancreatic serous cystadenoma) / Serous cystadenocarcinoma(英语:Serous ... Medullary carcinoma(英语:Medullary carcinoma). *Medullary carcinoma of the breast(英语:Medullary carcinoma of the breast) ... Lobular carcinoma(英语:Lobular carcinoma). *Lobular carcinoma in situ(英语:Lobular carcinoma in
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... Pancreatic cancer, islet cell. *Rectal cancer. Genitourinary and gynecologic[edit]. *Bladder cancer ... spindle cell carcinoma, and small-cell carcinoma.[citation needed] ... Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or ...
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ... Microscopic appearance is signet ring cell carcinoma, which is tumor cells with mucin droplet that displaces the nucleus to one ... particularly breast and lung carcinoma.[1] It is not associated with H. pylori infection or chronic gastritis. The risk factors ...
TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic ... and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor ...
胰管是將胰臟外分泌腺的分泌物(例如酶以及碳酸氫鹽)運輸出胰臟的組織,儘管構成胰管的上皮細胞只佔胰臟細胞總體積的10%[28],多數的胰臟腺癌始於胰管,稱為胰臟管腺癌(pancreatic ductal adenocarcinoma,PDAC)[29]。 ... adenosquamous carcinoma)、印戒細胞癌、肝樣細胞癌(英語:hepatoid carcinoma)、膠狀癌、未分化
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ... MEN I (3 Ps) - Pituitary, Parathyroid, Pancreatic. MEN IIa (2Ps, 1M) - Pheochromocytoma, Parathyroid, Medullary Thyroid Ca. MEN ... Sipple JH (1961). "The association of pheochromocytoma with carcinoma of the thyroid gland". Am. J. Med. 31: 163-6. doi:10.1016 ... In 1953 Underdahl et al. reported a case series of 8 patients with a syndrome of pituitary, parathyroid, and pancreatic islet ...
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ...
Ductal, lobular,. and medullary. Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ...
Hens JR, Dann P, Zhang JP, Harris S, Robinson GW, Wysolmerski J (March 2007). "BMP4 and PTHrP interact to stimulate ductal ... certain types of lung cancer including squamous cell lung carcinoma). However, it also has normal functions. ... "Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ... uterine serous carcinoma, Fallopian tube serous carcinoma, cervical serous carcinoma, and primary peritoneal serous carcinoma ... Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary peritoneal carcinoma, extra ... serous carcinoma, primary serous papillary carcinoma, psammomacarcinoma. It was historically classified under "carcinoma of ...
"Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal ... "Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. ". Dig Dis Sci. 2012. PMID 22615012. ...
Ductal, lobular,. and medullary (8500-8549). Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma ...
Ductal carcinoma in situ (DCIS) breast cancerEdit. "DCIS patients and control subjects did not differ with respect to oral ... "Alcoholics had only a modest 40% excess risk of pancreatic cancer … The excess risk for pancreatic cancer among alcoholics is ... Mastectomy specimen containing a very large cancer of the breast (in this case, an invasive ductal carcinoma). ... Nasopharynageal cancer / Nasopharyngeal carcinoma (NPC)Edit. Main article: Nasopharyngeal carcinoma. A systematic review found ...
Fill in any or all of the fields below. Click on the label to the left of each search field for more information or read the Help ...
Hints: Click on a [map] link to show a map of that region. Click on a [studies] link to search within your current results for studies in that region. Use the back button to return to this list and try another region. Studies with no locations are not included in the counts or on the map. Studies with multiple locations are included in each region containing locations ...
Immunofluorescence staining of normal pancreatic tissue and pancreatic ductal carcinoma. Formalin-fixed, paraffin-embedded ... Centrosome Abnormalities in Pancreatic Ductal Carcinoma. Norihiro Sato, Kazuhiro Mizumoto, Masafumi Nakamura, Kenjiro Nakamura ... Centrosome Abnormalities in Pancreatic Ductal Carcinoma. Norihiro Sato, Kazuhiro Mizumoto, Masafumi Nakamura, Kenjiro Nakamura ... Centrosome Abnormalities in Pancreatic Ductal Carcinoma. Norihiro Sato, Kazuhiro Mizumoto, Masafumi Nakamura, Kenjiro Nakamura ...
Abstract 1543: Clinical significance of ZNF185 intracellular localization in pancreatic ductal carcinoma. Daisuke Furukawa, ... Clinical significance of ZNF185 intracellular localization in pancreatic ductal carcinoma. [abstract]. In: Proceedings of the ... Abstract 1543: Clinical significance of ZNF185 intracellular localization in pancreatic ductal carcinoma ... Abstract 1543: Clinical significance of ZNF185 intracellular localization in pancreatic ductal carcinoma ...
Chemopreventive Potential of Oltipraz on BOP-Induced Ductal Pancreatic Carcinoma Development in Syrian Hamsters. ...
... and less pancreatic ductal and common biliary dilation. Keywords: acinar cell carcinoma, computed tomography, pancreatic ductal ... The percentage of common bile duct and pancreatic ductal dilation was 14.3% (2/14) and 7.1% (1/14), respectively. The mean size ... Pancreatic acinar cell carcinoma (ACC) is a rare tumor that is difficult to diagnose preoperatively. The aim of this study was ... features of ACC and compare the results with pancreatic ductal adenocarcinoma (DAC) for improving preoperative diagnosis. The ...
Identification and validation of differential expressed apoptotic genes in microdissected pancreatic ductal carcinomas. ... Identification and validation of differential expressed apoptotic genes in microdissected pancreatic ductal carcinomas ... Identification and validation of differential expressed apoptotic genes in microdissected pancreatic ductal carcinomas ... Identification and validation of differential expressed apoptotic genes in microdissected pancreatic ductal carcinomas ...
Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states.. N Suehara, K Mizumoto, T ... Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states.. N Suehara, K Mizumoto, T ... Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states.. N Suehara, K Mizumoto, T ... Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states. Message Subject (Your Name) ...
In this study, we analyzed the role of the uPAR/uPA system in both the development and progression of pancreatic cancer in ... Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a ... we analyzed the role of the uPAR/uPA system in both the development and progression of pancreatic cancer in invasive ductal ... We found overexpression of the uPAR in 48 of 50 invasive carcinomas as well as in a large proportion of high-grade PanIN ...
For primary cholangiocellular carcinoma (CCC)1 and metastases of pancreatic ductal adenocarcinoma (PDAC), however, the ... Cholangiocellular carcinoma (CCC) and pancreatic ductal adenocarcinoma (PDAC) are two highly aggressive cancer types that arise ... Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) ... Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) ...
Resection was performed in 85 patients with ampullary and in 150 with ductal pancreatic head carcinoma. Curative resection was ... Resection was performed in 85 patients with ampullary and in 150 with ductal pancreatic head carcinoma. Curative resection was ... For patients with pancreatic carcinoma, residual tumour stage, tumour size and grading were independent prognostic factors, but ... Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of ...
Carcinoma, Pancreatic ductal M384. Predesigned 384-well panel for use with SYBR® Green ...
The Sustained Induction of c-MYC Drives Nab-paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Erika Parasido ... The Sustained Induction of c-MYC Drives Nab-paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells ... The Sustained Induction of c-MYC Drives Nab-paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells ... The Sustained Induction of c-MYC Drives Nab-paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells ...
... puede explicar cómo una forma común del cáncer de pecho del temprano-escenario conocido como in situ de carcinoma ductal (DCIS ... Screening for pancreatic cancer using artificial intelligence. Dr. Ananya Malhotra. Dr. Ananya Malhotra speaks to News-Medical ... El estudio ofrece discernimiento en cómo el cáncer de pecho del temprano-escenario progresa al carcinoma ductal invasor. * ... El estudio ofrece nuevo discernimiento en cómo DCIS lleva al carcinoma ductal invasor (IDC), y ofrece una comprensión más sin ...
History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a ... Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. *For patients in Cohort 1: no prior ... A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma ... Pancreatic Adenocarcinoma Drug: Nab-Paclitaxel Drug: Gemcitabine Drug: Oxaliplatin Drug: Leucovorin Drug: Fluorouracil Drug: ...
History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a ... A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma ... Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. *For patients in Cohort 1: no prior ... tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma ( ...
Carcinoma, Pancreatic Ductal/blood supply. *Carcinoma, Pancreatic Ductal/genetics*. *Carcinoma, Pancreatic Ductal/pathology ... Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Long non-coding RNAs (lncRNAs) are important regulators in ... Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal ... Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa‐miR‐29b‐3p in pancreatic ductal ...
Build: Fri Jul 27 09:23:34 EDT 2018 (commit: a5c8d99). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
In this study, we found that the majority of pancreatic ductal adenocarcinoma tissues and cell lines had weak or no expression ... we found that overexpression of Net inhibited cell growth and survival and induced cell apoptosis in human pancreatic ductal ... Our data thus suggested that Net might play an important role in pancreatic carcinogenesis, possibly by acting as a tumor ... has been suspected of being involved in pancreatic cancer and other tumors biology. ...
Pancreatic Ductal" by people in this website by year, and whether "Carcinoma, Pancreatic Ductal" was a major or minor topic of ... "Carcinoma, Pancreatic Ductal" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH ( ... Carcinoma, Pancreatic Ductal*Carcinoma, Pancreatic Ductal. *Carcinomas, Pancreatic Ductal. *Ductal Carcinoma, Pancreatic ... Below are the most recent publications written about "Carcinoma, Pancreatic Ductal" by people in Profiles. ...
Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell 29, 229-240 (2016).. ... Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair. Stem Cell Res. ... Osteopontin is a novel marker of pancreatic ductal tissues and of undifferentiated pancreatic precursors in mice. Dev. Dyn. 235 ... and pancreatic duct glands (PDGs) (4, 5). These cells express the ductal/β-cell marker pancreatic and duodenal homeobox-1 gene ...
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. ...
This culture system is to date the closest surrogate to the parent carcinoma and harbors great potential as a drug sensitivity ... Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, which is mainly due to late diagnosis and profound resistance to ... Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies *Thao N. D. Pham ... Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, which is mainly due to late diagnosis and profound resistance to ...
Singh on invasive ductal carcinoma stage 2: Tubular carcinoma is a type of breast cancer that has a better prognosis. A ... carcinoma, unless stated to be in-situ, is by definition invasive. ... Prognosis for 3 pancreatic ampullary cancer tumors. 1 removed with whipple. Chemo 7months helped 1 shrink & 1 disappear. Liver ... Breast cancer: Tubular carcinoma is a type of breast cancer that has a better prognosis. A carcinoma, unless stated to be in- ...
Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and ... Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50. ... A hallmark in pancreatic ductal adenocarcinoma (PDA) is the presence of desmoplasia, which is defined as proliferation of ... Latent effects of fibronectin, α5β1 integrin, αVβ5 integrin, and the cytoskeleton regulate pancreatic carcinoma cell IL-8 ...
... knockdown of this lncRNA further reduces proliferation and invasion/migration of pancreatic carcinoma cells. ... The expression of HNRNPU processed transcript was increased in PDAC cell lines compared to noncancerous pancreatic cell lines. ... LNATM gapmer mediated inhibition of HNRNPU processed transcript reduced cell proliferation in Patu-T and PL45 pancreatic cancer ... adjacent benign pancreas and the pancreas from patients without pancreatic disease. Of the lncRNAs profiled, the expression of ...
Luttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Kloppel G. The grade of pancreatic ductal carcinoma is an independent ... 09.11.2017 , Pancreatic Tumors , Ausgabe 2/2018 T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal ... Xu Y, Lan S, Zheng Q. Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast. ... The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma: a systematic review and ...
PurposePancreatic ductal adenocarcinoma (PDAC) is one of the highest fatality rate cancers with poor survival rates. The tumor ... Pancreatic ductal adenocarcinoma (PDAC) is one of the highest fatality rate cancers with poor survival rates. The tumor ... Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma. Sci Rep (2018) 8(1):9912. ... Figure 1 Relationships between pancreatic ductal adenocarcinoma (PDAC) and normal pancreatic tissues. (A) Significant ...
... the incidence of pancreatic cancer has been increasing in recent years. The disease shows multigene, multi-step co.. ... Progress in Animal Models of Pancreatic Ductal Adeno-carcinoma. As a common gastrointestinal tumor, the incidence of pancreatic ... Furthermore , pancreatic cancer has an insidious onset and an extremely poor prognosis, so it is difficult to obtain cinical ... A large number of animal models of pancreatic cancer are currently available, including a cancer cell line-based xenograft, a ...
Since IPMNs include several pathologic types including invasive carcinoma, carcinoma in situ, adenoma, and hyperplasia, one ... Pancreatic Ductal Adenocarcinoma. Sixty-four patients with PDAC underwent surgical treatment; the resection rate was only 30.1 ... Development of Pancreatic Ductal Adenocarcinoma Associated with Intraductal Papillary Mucinous Neoplasia. Kazuo Inui, Junji ... In 6 of the 141 patients observed for intraductal papillary mucinous neoplasm (4.2%), pancreatic ductal adenocarcinoma ...
  • Pancreatic ductal adenocarcinoma (PDAC) remains an important cause of malignancy-related death and is the eigth most common cancer with the lowest overall 5-year relative survival rate. (
  • We then investigated the expression profile of these apoptosis-associated genes in microdissected tissue from 14 normal pancreatic ducts and 19 samples of PDAC using a virtual subarray from a whole genome analysis. (
  • Cholangiocellular carcinoma (CCC) and pancreatic ductal adenocarcinoma (PDAC) are two highly aggressive cancer types that arise from epithelial cells of the pancreatobiliary system. (
  • For primary cholangiocellular carcinoma (CCC) 1 and metastases of pancreatic ductal adenocarcinoma (PDAC), however, the distinction in a liver biopsy is basically an unsolvable task because of their high similarity. (
  • A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). (
  • Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. (
  • Oba A, Bao QR, Barnett CC, Al-Musawi MH, Croce C, Schulick RD, Del Chiaro M. Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC. (
  • Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, which is mainly due to late diagnosis and profound resistance to treatment. (
  • This culture system is to date the closest surrogate to the parent carcinoma and harbors great potential as a drug sensitivity testing system for the personalized treatment of PDAC. (
  • A gene array was used to profile the expression of 22,875 long non-coding RNAs (lncRNAs) and a large number of protein coding genes in 47 specimens of pancreatic ductal adenocarcinoma (PDAC), adjacent benign pancreas and the pancreas from patients without pancreatic disease. (
  • The expression of HNRNPU processed transcript was increased in PDAC cell lines compared to noncancerous pancreatic cell lines. (
  • Although lymph node (LN) metastases is considered a grave prognostic sign in pancreatic ductal adenocarcinoma (PDAC), patients with positive lymph nodes (PLN) constitute a heterogeneous group. (
  • Pancreatic ductal adenocarcinoma (PDAC) is one of the highest fatality rate cancers with poor survival rates. (
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading contributing factor of cancer -related death worldwide, exhibiting an extremely poor 5-year survival (less than 9%) ( 1 ). (
  • We presently investigated usefulness of intraductal ultrasonography (IDUS) as a precise diagnostic modality for IPMN and also examined long-term incidence of pancreatic ductal adenocarcinoma (PDAC) associated with IPMN of the branch duct type. (
  • The aim of this study was to investigate PROX1 and β-catenin expression in pancreatic ductal adenocarcinoma (PDAC). (
  • In pancreatic ductal adenocarcinoma (PDAC), the role of the Wnt/β-catenin signaling pathway is controversial because of the variable and sometimes paradoxical effects in the pancreas. (
  • In particular, the study aimed to examine the association between GLUT-1 expression and the therapeutic effect of chemoradiotherapy (CRT) in pancreatic ductal adenocarcinoma (PDAC). (
  • Pancreatic ductal adenocarcinoma (PDAC), which is considered incurable, accounts for more than 90% of pancreatic cancer cases. (
  • There is urgent need for biomarkers that provide early detection of pancreatic ductal adenocarcinoma (PDAC) as well as discrimination of autoimmune pancreatitis, as current clinical approaches are not suitably accurate for precise diagnosis. (
  • We used mass spectrometry to analyze protein profiles of more than 300 plasma specimens obtained from PDAC, noncancerous pancreatic diseases including autoimmune pancreatitis patients and healthy subjects. (
  • Pancreatic ductal adenocarcinoma (PDAC) is the fifth leading cause of cancer death in Japan with more than 24,000 deaths annually [ 1 ], while 35,000 deaths each year in the United States are caused by the disease [ 2 ]. (
  • In pancreas, acinar-to-ductal metaplasia has been proposed as an initiating mechanism for pancreatic ductal adenocarcinoma (PDAC). (
  • Differentiating intra-pancreatic distal bile duct carcinoma invading the pancreas from pancreatic ductal adenocarcinomas (PDAC) surrounding the distal common bile duct (CBD) can be challenging. (
  • The aim of this study was to validate a new definition of borderline resectable pancreatic ductal adenocarcinoma (PDAC) provided by the 2017 international consensus on the basis of three dimensions of anatomical (A), biological (B), and conditional (C) factors, using the data of the patients who had been registered for our institutional protocol of chemoradiotherapy followed by surgery (CRTS) for localized patients with PDAC. (
  • Pancreatic ductal adenocarcinoma (PDAC) is known to be a systemic disease at the time of diagnosis because approximately 30% of patients among those who undergo surgical resection die of the disease within 1 year after surgery [ 1 , 2 , 3 ]. (
  • Pancreatic ductal adenocarcinoma (PDAC) with difficulty in early diagnosis does not respond well to conventional treatments and has not occurred significant improvement in the overall 5-year survival rates. (
  • PC usually refers to pancreatic ductal adenocarcinoma (PDAC) which is the most common type of PCs. (
  • This study was to investigate the role of HOXC8 in pancreatic ductal adenocarcinoma (PDAC) growth and metastasis.Methods:The Hoxc8 expression was determined in 15 PDAC cell lines and human specimens by. (
  • BACKGROUND: Smad4, Smad6 and Smad7 are important molecules in TGF-beta pathway, which plays an important role in pancreatic ductal adenocarcinoma (PDAC) biology. (
  • We studied the expression of PSG1 in pancreatic adenocarcinoma (PDAC). (
  • OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumour thought to arise from ductal cells via pancreatic intraepithelial neoplasia (PanIN) precursor lesions. (
  • Modelling of different genetic events in mice suggests both ductal and acinar cells can give rise to PDAC. (
  • DESIGN: We examined the contribution of cellular origin to PDAC development by inducing PDAC-associated mutations, KrasG12D expression and Trp53 loss, specifically in ductal cells (Sox9CreER;KrasLSL-G12D;Trp53flox/flox ('Duct:KPcKO ')) or acinar cells (Ptf1aCreER;KrasLSL-G12D;Trp53flox/flox ('Acinar:KPcKO ')) in mice. (
  • MiRNA expression abnormalities in adenocarcinoma arising from pancreatic ductal system (PDAC) and Vater's papilla (PVAC) could be associated with distinctive pathologic features and clinical cancer behaviours. (
  • Here, we aim to clarify clinical-pathological and/or molecular features of this tumour subgroup through a systematic review coupled with a comparative analysis with existing databases, also providing indications for a correct approach to the clinical identification of MSI/dMMR pancreatic ductal adenocarcinoma (PDAC). (
  • In pancreatic ductal adenocarcinoma (PDAC) there is a near 100% frequency of KRAS mutations (Figure 1. (
  • Objective Pancreatic ductal adenocarcinoma (PDAC) is a disease of unmet medical need. (
  • However, little information has been published regarding the underlying functions and mechanisms of lncRNAs in pancreatic ductal adenocarcinoma (PDAC). (
  • The interest in liquid biopsy is growing because it could represent a non-invasive prognostic or predictive tool for clinical outcome in patients with pancreatic ductal adenocarcinoma (PDAC), an aggressive and lethal disease. (
  • Gene profiles were performed by digital droplet PCR in isolated CTCs, five primary PDAC tissues, and three different batches of RNA from normal human pancreatic tissue. (
  • Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal disease whose incidence rate is growing. (
  • Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal solid tumor due to the lack of reliable early detection markers and effective therapies. (
  • The microarray results were validated by qRT-PCR in PDAC tissues, paired adjacent normal pancreatic tissues, PDAC cell lines, and a normal pancreas cell line. (
  • Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PC, involving more than 90% of PCs, and its 5-year survival rate does not exceed 5% [ 2 ]. (
  • Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. (
  • With an overall 5-year survival rate of less than 8%, pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the worst prognosis ( 1 ). (
  • Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. (
  • Pancreatic ductal adenocarcinoma (PDAC), comprising over 90% of all pancreatic cancers, remains a lethal disease with an estimated 232,000 new cases, 227,000 deaths per year worldwide, and a less than 5% 5-y survival rate [1] , [2] . (
  • Background/Aim: We sought to identify the mechanisms of perineural invasion in pancreatic ductal adenocarcinoma (PDAC). (
  • Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with dismal prognosis and ranks as the fourth highest cause of cancer-related death in the United States ( 1 ). (
  • Pancreatic Ductal Adeno Carcinoma (PDAC) is a tumour in the exocrine part of the pancreas, in the acinar cells that excrete digestive enzymes into the intestine. (
  • Zhang, Rong 2018-02-05 00:00:00 Objectives To evaluate the diagnostic potential of intravoxel incoherent motion (IVIM) DWI for differentiating metastatic and non-metastatic lymph node stations (LNS) in pancreatic ductal adenocarcinoma (PDAC). (
  • Current guidelines support either immediate surgical resection or neoadjuvant therapy (NT) for patients with resectable pancreatic ductal adenocarcinoma (PDAC). (
  • Because NT is used increasingly for PDAC, efforts to reduce disparities will be critical in improving outcomes for all patients with pancreatic cancer. (
  • Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657). (
  • In this study, we analyzed the role of the uPAR/uPA system in both the development and progression of pancreatic cancer in invasive ductal adenocarcinomas of the pancreas (PDA) and their premalignant precursors (PanIN lesions) in 50 patients with long-term clinical follow-up. (
  • Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. (
  • Dusch N, Weiss C, Strobel P, Kienle P, Post S, Niedergethmann M. Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. (
  • We retrospectively investigated the incidence of pancreatic ductal adenocarcinoma among patients with intraductal papillary mucinous neoplasms of the pancreas. (
  • 2 of 26 patients (7.7%) subsequently developed pancreatic ductal adenocarcinoma in the remnant pancreas, at 41 months and 137 months after surgery. (
  • 1 ] reported an important relationship between IPMN and ductal adenocarcinoma of the pancreas: IPMN is a strong risk factor for pancreatic cancer. (
  • showed in mice that by introducing a β-catenin stabilizing mutation in CTNNB1 leads to pancreatic hypoplasia at an early phase of the developing pancreas. (
  • AIP has several characteristic features, such as infiltration of CD4-positive T cells and IgG4-positive plasmacytes, irregular narrowing of the pancreatic duct, and diffuse enlargement of the pancreas [ 7 - 9 ]. (
  • Thus, MMP-7 and FasL influence the initiation and maintenance of metaplastic events in pancreatic epithelium, explaining the observed link between metaplasia and apoptosis in pancreas and other gastrointestinal tissues. (
  • Familial pancreatic cancer (FPC) represents 9% of PC, and the risk of malignancy in kindred does not appear to be confined to the pancreas . (
  • The pancreatic duct, or duct of Wirsung (also, the major pancreatic duct due to the existence of an accessory pancreatic duct), is a duct joining the pancreas to the common bile duct. (
  • This supplies it with pancreatic juice from the exocrine pancreas, which aids in digestion. (
  • My main research focus is to understand the importance of pancreatic cancer and neoplasic cystic lesions of the pancreas (ie. (
  • Diseases associated with MUC6 include Pancreatic Ductal Carcinoma and Tumor Of Exocrine Pancreas . (
  • The diverse natural history of renal cell carcinoma (RCC) includes metastases to the pancreas, a very unusual site for distant spread of other cancers. (
  • Renal cell carcinoma metastatic to the pancreas: results of surgical management. (
  • Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. (
  • A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient. (
  • Pancreatic cancer starts in the cells of the pancreas. (
  • This type of cancer is called ductal adenocarcinoma of the pancreas. (
  • The pancreas has a series of small tubes that drain into the pancreatic duct. (
  • Surgeons usually consider pancreatic cancer to be resectable if it looks like it is still just in the pancreas or doesn't extend far beyond the pancreas, and has not grown into nearby large blood vessels. (
  • Neoplasia of the pancreas consists of a wide spectrum of benign and malignant tumors, with pancreatic ductal adenocarcinoma comprising 85% of malignant cases. (
  • Research Area: Body composition and inflammation in pancreatic neoplasms. (
  • 2014. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: Implications of minimal involvement of the main pancreatic duct. (
  • We report a case of the contemporaneous presence of two histologically different pancreatic neoplasms, one renal cancer and one embryogenic duodenal anomaly in a single patient. (
  • Other neoplasms may mimic pancreatic ductal carcinoma, particularly islet cell carcinoma and lymphoma. (
  • Pancreatic ductal adenocarcinomas (PDAs) are desmoplastic and can undergo epithelial-to-mesenchymal transition to confer metastasis and chemoresistance. (
  • Although pancreatic ductal adenocarcinomas (PDAs) widely express HER2, the expression level is generally low. (
  • pancreatic adenocarcinomas. (
  • What are useful modalities for staging ductal adenocarcinomas? (
  • About 95% of all pancreatic cancers are ductal adenocarcinomas. (
  • The loss of SMAD4, which as been reported to occur in 55% of pancreatic ductal adenocarcinomas may lead to up regulation of cell cycle proteins and hence increase cellular proliferation. (
  • In addition cell blocks from clinically diagnosed non-pancreatic adenocarcinomas were also selected as controls for this study (10 cases of colonic adenocarcinoma, 10 cases of pulmonary adenocarcinoma, 10 cases of breast ductal carcinoma and 10 cases of ovarian mucinous adenocarcinoma). (
  • The tissues included ductal carcinomas ( n = 13), adenomas ( n = 3), endocrine tumors ( n = 3), chronic pancreatitis ( n = 5), and normal pancreatic tissues ( n = 12). (
  • Pancreatic cancer is one of the most aggressive human tumors because of the challenges associated with detecting it at an early stage and its high potential for dissemination and distant metastasis. (
  • However, compared with DAC, we found that ACC tumors are likely to be larger and contain more heterogeneous intratumoral necrotic hypovascular regions, and less pancreatic ductal and common biliary dilation. (
  • Pancreatic tumors are rare in children and adolescents. (
  • Maspin methylation was analyzed by methylation-specific PCR in 100 invasive ductal breast carcinoma patients' tumors and circulating DNA in a prospective study. (
  • Pancreatic cancer is a genetic disease in which somatic mutations in the KRAS proto-oncogene are detected in a majority of tumors. (
  • We also describe techniques used to identify and characterize pancreatic tumors in adult transgenic fish. (
  • Identification and histological evaluation of KRAS-initiated pancreatic tumors in transgenic zebrafish. (
  • This study was undertaken to see the usefulness of CK19, CA19-9 and a newly described marker, SMAD4 in confirming the pancreatic origin of these tumors. (
  • In 6 of the 141 patients observed for intraductal papillary mucinous neoplasm (4.2%), pancreatic ductal adenocarcinoma developed. (
  • Histopathologic analysis of the surgical specimen revealed mild differentiated papillary renal carcinoma, intraductal papillary mucinous adenoma of the pancreatic head, foci of intraepithelial pancreatic neoplasm and pancreatic heterotopy of duodenal muscular and submucosal layers. (
  • What is the most common primary pancreatic neoplasm? (
  • These changes may lead to non-cancerous (benign) tumours such as a pancreatic pseudocyst or serous cystic neoplasm (SCN). (
  • Pancreatitis also can result in a focal pancreatic mass, simulating a neoplasm. (
  • Therefore, clarifying the biological mechanisms underlying distant metastasis from pancreatic cancer and accelerating the development of new treatment strategies are needed. (
  • Immunohistochemical staining of resected specimens and a xenograft model of liver metastasis was used to examine the relationship between distant metastasis in and the prognosis of pancreatic cancer and the expression of ZNF185. (
  • In conclusion, ZNF185 is a protein related to hematogenous metastasis, the expression of which in the plasma membrane was identified as an independent prognostic factor for pancreatic cancer. (
  • Hepatocellular carcinoma or hepatic metastasis from primaries such as pulmonary adenocarcinoma, colorectal adenocarcinoma, and breast carcinoma are usually easily distinguishable by morphology and means of known immunohistochemical markers. (
  • How fast does invasive ductal carcinoma develop metastasis? (
  • A hallmark in pancreatic ductal adenocarcinoma (PDA) is the presence of 'desmoplasia,' which is defined as proliferation of fibrotic tissue with an altered ECM conducive to tumor growth and metastasis. (
  • For this reason, a well-established preclinical model of pancreatic cancer must be established to allow further exploration of the occurrence, development, invasion, and metastasis mechanism of pancreatic cancer, as well as to facilitate research into new therapeutic targets. (
  • cutaneous metastasis of a pancreatic adenocarcinoma. (
  • We report a case of pancreatic metastasis from invasive ductal carcinoma 13 years after the initial diagnosis of breast cancer . (
  • When the pancreatic mass was discovered, it was believed to be a primary pancreatic cancer due to the long interval from the initial diagnosis of breast cancer to metastasis . (
  • Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma. (
  • Pancreatic cancer (PC) is a highly malignant tumor type that is characterized by aggressive invasion and a high incidence of metastasis. (
  • Fabre JM, Rouanet P, Dagues F, Blanc F, Baumel H, Domergue J. Various features and surgical approach of solitary pancreatic metastasis from renal cell carcinoma. (
  • Hirota T, Tomida T, Iwasa M, Takahashi K, Kaneda M, Tamaki H. Solitary pancreatic metastasis occurring eight years after nephrectomy for renal cell carcinoma. (
  • Surgical treatment of a solitary pancreatic metastasis from renal cell carcinoma: report of a case. (
  • At present, no standard protocols stipulate clinical treatment of pancreatic cancer, and the benefit rate of new targeted therapies is low. (
  • New Developments in the Treatment of Pancreatic Cancer. (
  • The results demonstrated that almost all pancreatic ductal carcinomas and some adenomas exhibited a striking defect in centrosome profiles, whereas normal pancreatic tissues and ductal cells of chronic pancreatitis tissues did not. (
  • Telomerase activity was measured in surgically resected tissues of 20 human pancreatic ductal carcinomas, 12 adenomas, 5 pancreatitis tissues, 14 normal pancreatic ducts, and 13 normal pancreatic tissues (primarily made up of acinar cells) using a PCR-based telomerase assay. (
  • A ) Human PDA and adjacent normal pancreatic tissues were subjected to hematoxylin and immunofluorescent staining with FAP and EpCAM. (
  • Those growing symmetrically around the CBD are more likely to be intra-pancreatic distal bile duct carcinomas and are associated with improved survival whereas cancers with asymmetric growth are more likely to have KRAS mutations and to be PDACs. (
  • Very recently, PSG expression has also been reported for squamous cell carcinomas and colorectal cancers [ 16 ]. (
  • The majority of exocrine pancreatic cancers are invasive ductal carcinomas. (
  • The 2004 Surgeon General report found convincing evidence for a direct causal relationship between tobacco use and the following cancers: lung and bronchial, laryngeal, oral cavity and pharyngeal, esophageal, stomach, pancreatic, kidney and renal pelvis, urinary bladder, and cervical cancers and acute myelogenous leukemia (AML). (
  • Circulating mesothelin is reported in nearly all pancreatic cancers, however the levels in healthy persons often exceed 80 ng/mL (using 40 kD molecular weight as the conversion factor) and to widely overlap the values in the pancreatic cancer patients. (
  • Using genetically-engineered mouse models that closely recapitulate human lung and pancreatic cancers, we have shown that gene mutations are permissive, but insufficient, to drive clonal cancer evolution, consistent with the need for additional cellular adaptations. (
  • Although surgical resection of localized pancreatic cancers is necessary for curative-intent treatment, most patients will develop recurrent disease. (
  • Sakaguchi T, Satoi S, Yamamoto T, Yamaki S, Sekimoto M. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. (
  • 2019. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma F. X. Real, ed. (
  • A minority of patients (15-20%) present with resectable disease as pancreatic cancer tends to metastasize to regional lymph nodes early in the course of the disease and many patients have subclinical liver metastases at the time of diagnosis. (
  • In the present study, we investigated the expression of ZNF185 in human pancreatic cancer in vivo and in clinical cases, and also evaluated its prognostic significance. (
  • For patients with pancreatic carcinoma, residual tumour stage, tumour size and grading were independent prognostic factors, but for those with ampullary carcinoma only tumour size was a prognostic factor. (
  • We identified 6 candidate prognostic markers for postoperative pancreatic cancer using FFPE tissues and immunohistochemically demonstrated high Nm23/NDPK-A expression to be a useful prognostic marker for pancreatic cancer. (
  • Proteomics has become a major tool for the discovery of diagnostic and prognostic cancer biomarkers, but pancreatic cancer analysis is challenging due to histological heterogeneity within the tumor. (
  • Takashi M, Takagi Y, Sakata T, Shimoji T, Miyake K. Surgical treatment of renal cell carcinoma metastases: prognostic significance. (
  • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. (
  • 2011. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. (
  • PURPOSE: This phase II trial is studying how well giving bevacizumab together with gemcitabine and oxaliplatin works in treating patients with metastatic pancreatic cancer. (
  • CONKO-001 study: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs . observation in patients with resected pancreatic cancer. (
  • E4201 study: a randomized phase III study of gemcitabine in combination with radiation therapy vs . gemcitabine alone in patients with localized, unresectable pancreatic cancer. (
  • AViTA study: a randomized, double-blind, placebo-controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer. (
  • CONKO-003 study: final results of a randomized trial in patients with gemcitabine-refractory pancreatic cancer. (
  • Whereas gemcitabine-based chemotherapy is standard in advanced pancreatic cancer, the role of adjuvant chemotherapy is still under discussion [ 7 ]. (
  • A prospective, open, multicenter, controlled phase III study was designed to evaluate the efficacy and toxicity of gemcitabine in pancreatic cancer patients after complete (R0 or R1) resection (Figure 1). (
  • Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. (
  • The treatment of isolated pancreatic metastases from renal cell carcinoma: a surgical review. (
  • Clinical study of renal cell carcinoma invading adjacent organs. (
  • Successful aggressive treatment against multiple intra-abdominal metastases from renal cell carcinoma 18 years after nephrectomy. (
  • Overexpression of PLAC8 was associated with the malignant progression and patients' poor prognosis in clear-cell renal cell carcinoma 15 . (
  • The aim of this study was to evaluate and describe the computed tomography (CT) features of ACC and compare the results with pancreatic ductal adenocarcinoma (DAC) for improving preoperative diagnosis. (
  • Computed tomography confirmed the renal lesion, but also a heterogeneous mass within the pancreatic head appeared without bile ducts dilatation. (
  • In addition, the effect of Ki- ras PM and p53 expression on a poor prognosis of pancreatic cancer may be different among various countries. (
  • These findings suggest that centrosome abnormalities may develop at a relatively early stage of pancreatic ductal carcinogenesis. (
  • Thus, our results indicate that reactivation of telomerase may occur at a late stage of pancreatic ductal carcinogenesis. (
  • Main objective is to establish evidence that broccoli sprouts rich in sulforaphane and quercetin as nutritional supplements increase the overall survival of patients with pancreatic ductal adenocarcinoma treated with conventional cytoreductive (radio-) chemotherapy. (
  • Pancreatic metastases from primary breast cancer are very rare. (
  • We reviewed the records of patients at three affiliated university hospital centers who had prior nephrectomy for RCC and subsequent pancreatic resection of metastases. (
  • The median interval from nephrectomy to diagnosis of pancreatic metastases was 83 months. (
  • Resection of pancreatic metastases from RCC is associated with long-term survival and should be considered for patients in whom complete resection is possible. (
  • An isolated pancreatic mass, that is, a mass with no ancillary CT or US findings of carcinoma (local extension, distant metastases), is a non-specific finding and requires further evaluation with either ERCP or angiography, and perhaps most importantly, with FNAB. (
  • The Union Internacional Contra la Cancrum classification system was not a reliable parameter of prognosis after resection of ampullary carcinoma. (
  • Here we show that matrix metalloproteinase-7 (MMP-7) is expressed not only in the majority of human pancreatic ductal adenocarcinoma specimens, but also in human pancreatic intraepithelial neoplasia and metaplastic duct lesions in human and mouse. (
  • We tried to understand this phenotypic alteration of pancreatic cancer cells by analysis of changes in gene activity and regulation of genes representing the apoptosis-pathway. (
  • Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma. (
  • These findings indicated not only that mutations in these two genes were the most common gene abnormalities in pancreatic cancer, but that the malignant progression of pancreatic cancer was accompanied by the progressive accumulation of multiple genetic abnormalities. (
  • Thus, the relationships of these two genes with pancreatic carcinogenesis have widely attracted the interests of oncologists. (
  • Acinar Cell Carcinoma » Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. (
  • Results Switchable CAR-T cells followed by administration of the switch directed against human epidermal growth factor receptor 2 (HER2)-induced complete remission in difficult-to-treat, patient-derived advanced pancreatic tumour models. (
  • What are critical vessels that can have a relationship of a tumour mass that is associated with ductal adenocarcinoma? (
  • Depending on how different the cells are from normal cells (differentiation) and how fast the cells are growing (grade) these tumours can be classified as a precancerous or cancerous tumour (called pancreatic neuroendocrine carcinoma). (
  • AIMS: To evaluate mRNA and protein expression of signal transducers and activators of transcription (STAT)3 in colorectal carcinomas (CRCs) and to define the association of STAT3 activity with the STAT3-inducible targets cyclin D1, survivin, Bcl-xl and Mcl-1. (
  • However, the preferential mutation of KRAS versus NRAS in colorectal carcinoma (CRC) cannot be explained simply on this basis. (
  • An analysis of HER-2/neu gene status in invasive ductal carcinomas using immunohistochemistry and fluorescence in situ hybridization. (
  • The pancreatic duct joins the common bile duct just prior to the ampulla of Vater, after which both ducts perforate the medial side of the second portion of the duodenum at the major duodenal papilla. (
  • A gallstone may get lodged in the constricted distal end of the ampulla of Vater, where it blocks the flow of both bile and pancreatic juice into the duodenum. (
  • Targeting the HGF/c-MET pathway in hepatocellular carcinoma. (
  • Stereotactic Body Radiotherapy: What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma? (
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial. (
  • KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. (
  • Effect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trial. (
  • Randomized, Open Label, Multicenter, Phase II Trial comparing Transarterial Chemoembolization (TACE) plus Sorafenib with TACE Alone in Patients with Hepatocellular Carcinoma (HCC): TACTICS Trial. (
  • Pancreatic acinar cell carcinoma (ACC) is a rare tumor that is difficult to diagnose preoperatively. (
  • Here, we report the case of a 15-year-old boy who presented with a mixed acinar cell carcinoma/ductal adenocarcinoma with blastomatous components. (
  • The periphery of acinar cell carcinoma is generally circumscribed with minimal stroma within the tumor. (
  • Acinar cell differentiation of the tumor can be further confirmed by the presence of pancreatic exocrine enzymes, such as trypsin and elastase. (
  • Carcinoma that arises from the PANCREATIC DUCTS. (
  • Termination pattern of main and accessory pancreatic ducts among Tanzanians. (
  • Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. (
  • Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. (
  • In patients with pancreatic cancer, early diagnosis and treatment would have a great impact on survival time. (
  • The aim of this meta-analysis is to summarize the predicting role of TLRs for survival in patients with a variety of carcinomas. (
  • Although rates of pancreatic cancer have slowly declined in the United States over the past 15-25 years, it is the fourth leading cause of cancer mortality [ 1 ], with a 5-year survival rate of as low as 5% [ 2 ]. (
  • Majority of patients have advanced pancreatic cancer at the time of diagnosis. (
  • These markers, when used as a panel, may confirm the diagnosis of pancreatic adenocarcinoma in fine needle aspiration samples, and help in differentiating from metastatic adenocarcinoma. (
  • Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. (
  • IBD CT is the single best modality for diagnosis and staging of patients with suspected pancreatic carcinoma. (
  • These diseases usually respond to therapy and thus it is essential to confirm the radiologic diagnosis of pancreatic carcinoma with biopsy, particularly if surgery is not planned or if chemoradiation therapy is anticipated. (
  • A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). (
  • How do you determine the chance for resection for ductal adenocarcinoma? (
  • Soto JL, Barbera VM, Saceda M, Carrato A. Molecular biology of exocrine pancreatic cancer. (
  • This information is about treating exocrine pancreatic cancer, the most common type of pancreatic cancer. (
  • These results suggest that centrosome abnormalities can occur early in the multistep process of pancreatic ductal carcinogenesis and that detection of these abnormalities may be of value for assessing the underlying malignant potential in pancreatic lesions. (
  • We found overexpression of the uPAR in 48 of 50 invasive carcinomas as well as in a large proportion of high-grade PanIN lesions by immunohistochemistry and in situ hybridization. (
  • Since IPMNs include several pathologic types including invasive carcinoma, carcinoma in situ, adenoma, and hyperplasia, one needs to distinguish benign from malignant lesions to avoid unnecessary surgery. (
  • Results after pancreatic resection for metastatic lesions. (
  • LNA TM gapmer mediated inhibition of HNRNPU processed transcript reduced cell proliferation in Patu-T and PL45 pancreatic cancer cell lines. (
  • PLAC8 also acted as a novel biomarker in liver carcinoma 13 , and PLAC8 recovery could suppress PI3K/Akt/GSK3b/Wnt/β-catenin signaling to reduce cell proliferation 14 . (
  • Therefore, telomerase may be a specific marker for distinguishing pancreatic cancer from pancreatitis and adenomas. (
  • Pancreatic fibroblasts were initially grown from surgical specimens from a 33-year-old male patient with chronic pancreatitis and were used at five to six passages. (
  • Future strategies should aim at using those regimens to achieve more RO surgical resections as the only curative treatment for pancreatic cancer. (
  • This book provides state of the art knowledge on a broad range of clinical issues in pancreatic cancer, covering topics from screening and pathophysiology to surgical treatments. (
  • The percentage of common bile duct and pancreatic ductal dilation was 14.3% (2/14) and 7.1% (1/14), respectively. (
  • Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. (
  • Our aim is to identify clinical, morphological, and genetic features characteristic of intra-pancreatic distal bile duct carcinoma. (
  • Most people have just one pancreatic duct. (
  • However, some have an additional accessory pancreatic duct, also called the Duct of Santorini. (
  • An accessory pancreatic duct can be functional or non-functional. (
  • In the other 30% of people, it drains into the main pancreatic duct, which drains into the duodenum via the major duodenal papilla. (
  • The main pancreatic duct and the accessory duct both eventually-either directly or indirectly-connect to the second part ('D2', the vertical segment) of the duodenum. (
  • Formation of an accessory pancreatic duct Compression, obstruction or inflammation of the pancreatic duct may lead to acute pancreatitis. (
  • Bile backing up into the pancreatic duct may initiate pancreatitis. (
  • The pancreatic duct is generally regarded as abnormally enlarged if being over 3 mm in the head and 2 mm in the body or tail. (
  • The pancreatic duct is also called the duct of Wirsung. (
  • ERCP image showing the pancreatic duct and biliary tree. (
  • Pancreatic duct Deep dissection.Anterior view. (
  • Ultrasonography of a dilated pancreatic duct (in this case 9mm) due to pancreatic cancer. (
  • The pancreatic duct joins the common bile duct and empties into the duodenum. (
  • The juice travels through the pancreatic duct into the duodenum. (
  • The poor prognosis of pancreatic ductal adenocarcinoma is mainly attributed to its insidious and inconspicuous growth often presenting late in the clinical disease process. (
  • In this paper, we present the distinctive features of the currently popular pancreatic cancer models, and discuss their preparation methods, clinical relations, scientific purposes and limitations. (
  • Can cyberknife surgery be used for squamous cell carcinoma? (
  • In squamous cell carcinomas, HRAS is the predominant isoform mutated (8%), followed by KRAS (3%) and NRAS (2%) (Catalogue of Somatic Mutations In Cancer [COSMIC] database). (
  • Therefore, we examined centrosomes in human pancreatic tissue sections obtained from patients with ductal carcinoma and other pathological states to evaluate whether centrosome abnormalities are specific for cancer cells in situ , and thus the presence of such abnormalities could be a sensitive diagnostic marker. (
  • Cells expressing ZNF185 in the plasma membrane were detected in 71 (39.0%) out of 182 patients with resected pancreatic cancer. (
  • Relative telomerase activity was expressed as the equivalent telomerase intensity of the number of cells of a human pancreatic cancer cell line, MIA PaCa-2, per microgram of protein in the tissue samples. (
  • Accumulating evidence indicates that pancreatic stellate cells when activated switch to a myofibroblast phenotype that produces components of the extracellular matrix, MMPs, and tissue inhibitors of MMPs by activating the mitogen-activated protein kinase (extracellular signal-regulated kinase 1/2) pathway. (
  • In this prevailing model, a three-dimensional structure supports epithelial carcinoma cells through an altered extracellular matrix (ECM), maintained by diffusible paracrine growth factors and cytokines, tumor-associated vasculature, inflammatory cells, and stromal fibroblasts. (
  • New evidence indicates that mutations arising in stromal fibroblasts and consequent manifestation of paracrine factors promote growth and proliferation of carcinoma cells ( 2 ). (
  • knockdown of this lncRNA further reduces proliferation and invasion/migration of pancreatic carcinoma cells. (
  • Epigenetic regulation of maspin expression in human ovarian carcinoma cells. (
  • But in some cases, changes to pancreatic cells can cause cancer. (
  • Exocrine cells make and release pancreatic juice. (
  • We recently demonstrated, for example, that pancreatic cancer cells tolerate genetic ablation of their initiating oncogene KRAS through rewiring of signal transduction. (
  • Un nuevo modelo genético-basado puede explicar cómo una forma común del cáncer de pecho del temprano-escenario conocido como in situ de carcinoma ductal (DCIS) progresa a una forma más invasor del cáncer dice a investigadores en El Doctor en Medicina centro de la Universidad de Texas del cáncer de Anderson. (
  • This model offers a close approximation of the in situ tumor in the patient, as the slices contain all the constituent cell types and acellular components that are resident in pancreatic cancer in their original configuration. (
  • A carcinoma, unless stated to be in-situ, is by definition invasive. (
  • Aim: To determine the concordance rates between results from immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays for the HER-2/neu gene in cases of invasive ductal carcinoma. (
  • Is Ductal Carcinoma in Situ Cancer? (
  • 3. Malignancy (within the past two years) except for non-melanomatous skin cancer or carcinoma in situ of the cervix, uterus, or bladder. (
  • Pancreatic adenocarcinoma patients who had diabetes mellitus had higher HOMA-IR (p (
  • KRAS mutations represent an early event during pancreatic tumorigenesis, crucial for cancer initiation and progression. (
  • In this chapter, we review our experience using the Gal4/UAS system to model KRAS-initiated pancreatic cancer in zebrafish, as well as our early efforts using this system to study the influence of other cooperating oncogenes. (
  • The two groups with poor prognosis (n = 4) and with better prognosis (n = 4) had been carefully chosen among 96 resected cases of pancreatic cancer during 1998 to 2007 in Tohoku University Hospital. (
  • As a common gastrointestinal tumor, the incidence of pancreatic cancer has been increasing in recent years. (
  • When the cutoff value of relative telomerase activity was set at 1.00 and 3.00, the positivity rates of telomerase activity in pancreatic ductal carcinomas were 100 and 80%, respectively. (